View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Oct. 27, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	DENTSPLY INTERNATIONAL INC /DE/
Entity Central Index Key	0000818479
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Trading Symbol	XRAY
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		139,866,493

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net sales	$ 648.9	$ 708.2	$ 2,003.2	$ 2,203.6
Cost of products sold	279.4	320.1	860.7	996.9
Gross profit	369.5	388.1	1,142.5	1,206.7
Selling, general and administrative expenses	264.3	276.0	809.5	859.9
Restructuring and other costs	6.6	2.5	50.9	4.5
Operating income	98.6	109.6	282.1	342.3
Other income and expenses:
Interest expense	9.6	12.7	30.1	35.4
Interest income	(0.4)	(1.4)	(1.8)	(4.6)
Other expense (income), net	(3.8)	0.8	(3.6)	1.8
Income before income taxes	93.2	97.5	257.4	309.7
Provision for income taxes	19.6	21.2	63.2	69.9
Equity in net income (loss) of unconsolidated affiliated company	10.8	(1.0)	(1.7)	(1.6)
Net income	84.4	75.3	192.5	238.2
Less: Net (loss) income attributable to noncontrolling interests	(0.1)	0.0	(0.1)	0.1
Net income attributable to DENTSPLY International	$ 84.5	$ 75.3	$ 192.6	$ 238.1
Earnings per common share:
Basic (in dollars per share)	$ 0.60	$ 0.53	$ 1.38	$ 1.68
Diluted (in dollars per share)	$ 0.59	$ 0.52	$ 1.35	$ 1.65
Weighted average common shares outstanding:
Basic (in shares)	139.8	141.8	140.0	141.9
Diluted (in shares)	142.4	144.3	142.5	144.3

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 84.4	$ 75.3	$ 192.5	$ 238.2
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	(37.7)	(198.6)	(150.6)	(227.3)
Net gain on derivative financial instruments	1.1	35.9	9.0	38.1
Net unrealized holding (loss) gain on available-for-sale securities	(78.8)	3.6	(8.5)	(0.2)
Pension liability adjustments	2.9	3.8	4.3	5.0
Total other comprehensive income (loss), net of tax	(112.5)	(155.3)	(145.8)	(184.4)
Total comprehensive income	(28.1)	(80.0)	46.7	53.8
Less: Comprehensive income attributable to noncontrolling interests	0.0	(0.3)	0.5	(0.4)
Net (decrease) increase in other comprehensive income	$ (28.1)	$ (79.7)	$ 46.2	$ 54.2

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 236.4	$ 151.6
Accounts and notes receivables-trade, net	429.8	426.6
Inventories, net	361.3	387.1
Prepaid expenses and other current assets, net	180.6	241.7
Total Current Assets	1,208.1	1,207.0
Property, plant and equipment, net	555.2	588.9
Identifiable intangible assets, net	600.4	670.8
Goodwill, net	1,984.3	2,089.3
Other noncurrent assets, net	54.2	90.5
Total Assets	4,402.2	4,646.5
Current Liabilities:
Accounts payable	137.5	132.6
Accrued liabilities	309.1	379.2
Income taxes payable	33.6	29.0
Notes payable and current portion of long-term debt	453.2	111.8
Total Current Liabilities	933.4	652.6
Long-term debt	701.9	1,150.1
Deferred income taxes	152.9	165.6
Other noncurrent liabilities	332.5	356.0
Total Liabilities	2,120.7	2,324.3
Commitments and contingencies
Equity:
Preferred stock, $1.00 par value; .25 million shares authorized; no shares issued	0.0	0.0
Common stock, $.01 par value; 200.0 million shares authorized; 162.8 million shares issued at September 30, 2015 and December 31, 2014	1.6	1.6
Capital in excess of par value	232.0	221.7
Retained earnings	3,542.7	3,380.7
Accumulated other comprehensive loss	(587.5)	(441.1)
Treasury stock, at cost, 23.0 million and 21.9 million shares at September 30, 2015 and December 31, 2014, respectively	(908.7)	(841.6)
Total DENTSPLY International Equity	2,280.1	2,321.3
Noncontrolling interests	1.4	0.9
Total Equity	2,281.5	2,322.2
Total Liabilities and Equity	$ 4,402.2	$ 4,646.5

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 1.00	$ 1.00
Preferred stock, shares authorized	250,000.00	250,000.00
Preferred stock, shares issued	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000.0
Common stock, shares issued	162,800,000	162,800,000
Treasury stock, shares	23,000,000	21,900,000

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income	$ 192.5	$ 238.2
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	61.6	63.1
Amortization	32.8	36.4
Amortization of deferred financing costs	3.3	3.5
Deferred income taxes	39.2	4.6
Share-based compensation expense	19.5	19.9
Restructuring and other costs - non-cash	37.8	0.0
Stock option income tax benefit	(10.0)	(0.4)
Equity in net loss from unconsolidated affiliates	1.7	1.6
Other non-cash income	(10.0)	3.6
Loss on disposal of property, plant and equipment	0.6	0.0
Changes in operating assets and liabilities, net of acquisitions:
Accounts and notes receivable-trade, net	(27.9)	(30.9)
Inventories, net	10.1	(5.7)
Prepaid expenses and other current assets, net	(7.0)	(12.4)
Other noncurrent assets, net	4.1	0.3
Accounts payable	11.2	1.9
Accrued liabilities	4.6	7.6
Income taxes	(7.2)	27.9
Other noncurrent liabilities	14.1	8.5
Net cash provided by operating activities	371.0	367.7
Cash flows from investing activities:
Capital expenditures	(51.7)	(73.0)
Cash paid for acquisitions of businesses, net of cash acquired	(3.3)	(2.0)
Cash received from sale of business or product line	0.0	1.4
Cash received on derivatives contracts	22.4	4.9
Cash paid on derivatives contracts	(0.8)	(4.9)
Expenditures for identifiable intangible assets	0.0	(1.3)
Purchase of short-term investments	0.0	(2.3)
Liquidation of short-term investments	0.0	1.1
Proceeds from redemption of Corporate Bonds	47.7	0.0
Purchase of Company-owned life insurance policies	(1.4)	(0.9)
Proceeds from sale of property, plant and equipment, net	0.3	0.6
Net cash provided by (used in) investing activities	13.2	(76.4)
Cash flows from financing activities:
Increase (decrease) in short-term borrowings	0.9	(99.8)
Cash paid for treasury stock	(112.7)	(70.8)
Cash dividends paid	(29.9)	(27.9)
Cash paid for acquisition of noncontrolling interests of consolidated subsidiary	(80.4)	0.0
Proceeds from long-term borrowings	0.0	114.1
Repayments on long-term borrowings	(109.1)	(199.0)
Proceeds from exercised stock options	27.2	18.7
Excess tax benefits from share-based compensation	10.0	0.4
Net cash used in financing activities	(294.0)	(264.3)
Effect of exchange rate changes on cash and cash equivalents	(5.4)	(4.3)
Net increase in cash and cash equivalents	84.8	22.7
Cash and cash equivalents at beginning of period	151.6	75.0
Cash and cash equivalents at end of period	$ 236.4	$ 97.7

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Millions	Total	Common Stock	Capital in Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Total DENTSPLY International Equity	Noncontrolling Interests
Beginning Balance at Dec. 31, 2013	$ 2,577.9	$ 1.6	$ 255.3	$ 3,095.7	$ (69.1)	$ (748.5)	$ 2,535.0	$ 42.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	238.2			238.1			238.1	0.1
Other comprehensive (loss) gain	(178.9)				(178.5)		(178.5)	(0.4)
Other comprehensive (loss) gain	(184.4)
Acquisition of noncontrolling interest	(82.7)		(35.8)		(5.5)		(41.3)	(41.4)
Exercise of stock options	18.7		(3.3)			22.0	18.7
Tax benefit from stock options exercised	0.4		0.4				0.4
Share based compensation expense	19.9		19.9				19.9
Funding of Employee Stock Ownership Plan	5.9		1.5			4.4	5.9
Treasury shares purchased	(70.7)					(70.7)	(70.7)
RSU distributions	(4.3)					6.9	(4.3)
RSU dividends				(0.2)
Cash dividends ($0.21750 per share)	(28.2)			(28.2)			(28.2)
Ending Balance at Sep. 30, 2014	2,496.2	1.6	227.0	3,305.4	(253.1)	(785.9)	2,495.0	1.2
Beginning Balance at Dec. 31, 2014	2,322.2	1.6	221.7	3,380.7	(441.1)	(841.6)	2,321.3	0.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	192.5			192.6			192.6	(0.1)
Other comprehensive (loss) gain	(145.8)				(146.4)		(146.4)	0.6
Exercise of stock options	27.0		(6.2)				27.0
Tax benefit from stock options exercised	10.0		10.0				10.0
Share based compensation expense	19.4		19.4				19.4
Funding of Employee Stock Ownership Plan	4.8		1.1			3.7	4.8
Treasury shares purchased	(112.7)					(112.7)	(112.7)
RSU distributions	(5.6)		(14.3)			8.7	(5.6)
RSU dividends			0.3	(0.3)
Cash dividends ($0.21750 per share)	(30.3)			(30.3)
Ending Balance at Sep. 30, 2015	$ 2,281.5	$ 1.6	$ 232.0	$ 3,542.7	$ (587.5)	$ (908.7)	$ 2,280.1	$ 1.4

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Statement of Stockholders' Equity [Abstract]
Cash dividends, per share	$ 0.21750	$ 0.19875

SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

The accounting policies of the Company, as applied in the interim consolidated financial statements presented herein are substantially the same as presented in the Company’s Form 10-K, as for the year ended December 31, 2014, as revised on Form 8-K filed October 28, 2015, except as may be indicated below:

Accounts and Notes Receivable

The Company records a provision for doubtful accounts, which is included in “Selling, general and administrative expenses” in the Consolidated Statements of Operations.

Accounts and notes receivables – trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $10.0 million at September 30, 2015 and $8.8 million at December 31, 2014.

Marketable Securities

The Company’s marketable securities consisted of DIO Corporation (“DIO”) corporate convertible bonds that were classified as available-for-sale in “Prepaid expenses and other current assets” on the Consolidated Balance Sheets as the instruments were to mature in December 2015. Changes in the fair value of the bonds were reported in accumulated other comprehensive income (“AOCI”).

During the three months ended September 30, 2015, the Company sold the convertible bonds at face value for $47.7 million. As a result of the sale, the Company recorded an unrealized holding loss, net of tax, of $4.8 million for the nine months ended September 30, 2015, in the Consolidated Statements of Comprehensive Income. The fair value of the convertible bonds was $57.7 million at December 31, 2014 and included a cumulative unrealized holding gain of $8.5 million on available-for-sale securities, net of tax, which was recorded in AOCI.

As part of the disposition of the convertible bonds, the Company requested to relinquish its two board seats on the DIO Board of Directors. Subsequent to September 30, 2015, the Company no longer has representation on the DIO Board of Directors and as a result the Company no longer has significant influence on the operations of DIO. The Company will begin accounting for the remaining direct investment using the cost-basis method of accounting effective in the fourth quarter of 2015.

New Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.” This newly issued accounting standard changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. This standard will have the impact of reducing the frequency of disposals reported as discontinued operations, by requiring such a disposal to represent a strategic shift that has or will have a major effect on entity’s operations and financial results. Additionally, existing provisions that prohibit an entity from reporting a discontinued operation if it has certain continuing cash flows or involvement with the component after a disposal are eliminated by this standard. The ASU also expands the disclosures for discontinued operations and requires new disclosures related to individually significant disposals that do not qualify as discontinued operations. This Company adopted this accounting standard for the quarter ended March 31, 2015. The adoption of this standard did not materially impact the Company’s financial position or results of operations.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” that seeks to provide a single, comprehensive revenue recognition model for all contracts with customers that improve comparability within industries, across industries and across capital markets. Under this standard, an entity should recognize revenue for the transfer of goods or services equal to the amount it expects to be entitled to receive for those goods or services. Enhanced disclosure requirements regarding the nature, timing and uncertainty of revenue and related cash flows exist. To assist entities in applying the standard, a five step model for recognizing and measuring revenue from contracts with customers has been introduced. Entities have the option to apply the new guidance retrospectively to each prior reporting period presented (full retrospective approach) or retrospectively with a cumulative effect adjustment to retained earnings for initial application of the guidance at the date of initial adoption (modified retrospective method). The Company expects to adopt this accounting standard for the quarter ended March 31, 2018. Early adoption is not permitted. On April 1, 2015, the FASB proposed deferring the effective date by one year to annual reporting periods beginning after December 15, 2017. The proposal was approved on July 9, 2015. The Company is currently assessing the impact that ASU No. 2014-09 may have on their financial positions, results of operations, cash flows and disclosures, as well as, the transition method they will use to adopt the guidance.

In January 2015, the FASB issued ASU No. 2015-01, “Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items” This newly issued accounting standard eliminates from generally accepted accounting principles the concept of Extraordinary items, events or transactions that are unusual in nature and occur infrequently. The amendments in this update are effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2015. Prospective application and early adoption is permitted. The adoption of this standard is not expected to impact the Company’s financial position or results of operations.

In April 2015, the FASB issued ASU No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs.” This newly issued accounting standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction from the carrying amount of that debt liability. Retrospective application is required. The amendments in this standard are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company adopted this standard during the second quarter of 2015, applying retrospective application to the periods presented below. The following is a summary of the adjustment to the financial statement line items impacted by this accounting update:



December 31, 2014
(in millions)	As Reported
Consolidated Balance Sheet Line Item	Balance		Adjustment			Adjusted Balance
Other noncurrent assets, net	$	94.3	$	(3.8	)	$	90.5
Notes payable and current portion of long-term debt	112.8		(1.0		)	111.8
Long-term debt	1,152.9		(2.8		)	1,150.1



March 31, 2015
(in millions)	As Reported
Consolidated Balance Sheet Line Item	Balance		Adjustment			Adjusted Balance
Other noncurrent assets, net	$	61.3	$	(3.6	)	$	57.7
Notes payable and current portion of long-term debt	247.6		(0.9		)	246.7
Long-term debt	1,078.8		(2.6		)	1,076.2

In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory.” This newly issued accounting standard requires that an entity measure inventory at the lower of cost or net realizable value, as opposed to the lower of cost or market value. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Excluded from this update are the Last In First Out (“LIFO”) and retail inventory methods of accounting for inventory. The amendments in this standard are effective for fiscal years beginning after December 15, 2016 and for interim periods within fiscal years beginning after December 15, 2017. Prospective application is required for presentation purposes. The adoption of this standard is not expected to impact the Company’s financial position or results of operations.

In September 2015, the FASB issued 2015-16, “Simplifying Accounting for Measurement Period Adjustments.” This newly issued accounting standard seeks to simplify the accounting related to Business Combinations. Current US GAAP requires retrospective adjustment for provisional amounts recognized during the measurement periods when facts and circumstances that existed at the measurement date, if known, would have affected the measurement of the accounts initially recognized. This standard eliminates the requirement for retrospective adjustments and requires adjustments to the Financial Statements as needed in current period earnings for the full effect of changes. The adoption of this standard is required for interim and fiscal periods ending after December 15, 2015 and is not permitted to be adopted retrospectively. As such, the Company will incorporate this standard into the accounting and reporting for all future business combinations that take place once the standard becomes effective.

STOCK COMPENSATION

9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK COMPENSATION

The following table represents total stock based compensation expense for non-qualified stock options, restricted stock units (“RSU”) and the tax related benefit for the three and nine months ended September 30, 2015 and 2014:



	Three Months Ended				Nine Months Ended
(in millions)	2015		2014		2015		2014

Stock option expense	$	2.3	$	2.2	$	6.0	$	6.6
RSU expense	5.1		4.0		12.5		12.1
Total stock based compensation expense	$	7.4	$	6.2	$	18.5	$	18.7

Total related tax benefit	$	2.1	$	1.6	$	5.5	$	5.1

For the three and nine months ended September 30, 2015, stock compensation expense of $7.4 million and $18.5 million, respectively, of which, $7.1 million and $18.0 million, respectively, was recorded in Selling, general and administrative expense and $0.3 million and $0.5 million, respectively, was recorded in Cost of products sold in the Consolidated Statement of Operations. For the three and nine months ended September 30, 2014, stock compensation expense of $6.2 million and $18.7 million, respectively, of which, $6.0 million and $18.2 million, respectively, was recorded in Selling, general and administrative expense and $0.2 million and $0.5 million, respectively, was recorded in Cost of products sold in the Consolidated Statement of Operations.

At September 30, 2015, the remaining unamortized compensation cost related to non-qualified stock options is $11.5 million, which will be expensed over the weighted average remaining vesting period of the options, or approximately 1.5 years. At September 30, 2015, the unamortized compensation cost related to RSU is $24.8 million, which will be expensed over the weighted average remaining restricted period of the RSU, or approximately 1.3 years.

COMPREHENSIVE INCOME

9 Months Ended

Sep. 30, 2015

COMPREHENSIVE INCOME [Abstract]

COMPREHENSIVE INCOME

During the quarter ended September 30, 2015, foreign currency translation adjustments included currency translation gains of $2.3 million and gains on the Company’s loans designated as hedges of net investments of $0.5 million. During the quarter ended September 30, 2014, foreign currency translation adjustments included currency translation gains of $201.8 million and gains of $9.0 million on the Company’s loans designated as hedges of net investments. During the nine months ended September 30, 2015, foreign currency translation adjustments included currency translation losses of $150.4 million and losses on the Company’s loans designated as hedges of net investments of $0.8 million. During the nine months ended September 30, 2014, foreign currency translation adjustments included currency translation gains of $227.2 million and gains on the Company’s loans designated as hedges of net investments of $5.9 million. These amounts are recorded in AOCI, net of any related tax adjustments. At September 30, 2015 and December 31, 2014, these tax adjustments were $185.5 million and $195.4 million, respectively, primarily related to foreign currency translation adjustments.

The cumulative foreign currency translation adjustments included translation losses of $267.5 million and $117.1 million at September 30, 2015 and December 31, 2014, respectively, and losses on loans designated as hedges of net investments of $96.2 million and $95.4 million, respectively. These foreign currency translation adjustments were partially offset by movements on derivative financial instruments, which are discussed in Note 10, Financial Instruments and Derivatives.

Changes in AOCI, net of tax, by component for the nine months ended September 30, 2015 and 2014:



(in millions)	Foreign Currency Translation Adjustments			Gain and (Loss) on Derivative Financial Instruments Designated as Cash Flow Hedges			Gain and (Loss) on Derivative Financial Instruments Designated as Net Investment Hedges			Net Unrealized Holding Gain (Loss) on Available-for-Sale Securities			Pension Liability Adjustments			Total

Balance at December 31, 2014	$	(212.5	)	$	(10.8	)	$	(112.7	)	$	8.5		$	(113.6	)	$	(441.1	)
Other comprehensive income (loss) before reclassifications	(151.2		)	15.4			4.4			(4.8		)	—			(136.2		)
Amounts reclassified from accumulated other comprehensive income (loss)	—			(10.8		)	—			(3.7		)	4.3			(10.2		)
Net (decrease) increase in other comprehensive income	(151.2		)	4.6			4.4			(8.5		)	4.3			(146.4		)

Balance at September 30, 2015	$	(363.7	)	$	(6.2	)	$	(108.3	)	$	—		$	(109.3	)	$	(587.5	)



(in millions)	Foreign Currency Translation Adjustments			Gain and (Loss) on Derivative Financial Instruments Designated as Cash Flow Hedges			Gain and (Loss) on Derivative Financial Instruments Designated as Net Investment Hedges			Net Unrealized Holding Gain (Loss)on Available-for-Sale Securities			Pension Liability Adjustments			Total

Balance at December 31, 2013	$	141.0		$	(21.8	)	$	(151.1	)	$	12.7		$	(49.9	)	$	(69.1	)
Other comprehensive income (loss) before reclassifications	(221.3		)	4.5			27.5			(0.2		)	3.6			(185.9		)
Amounts reclassified from accumulated other comprehensive income (loss)	—			6.0			—			—			1.4			7.4
Net (decrease) increase in other comprehensive income	(221.3		)	10.5			27.5			(0.2		)	5.0			(178.5		)
Foreign currency translation related to acquisition of noncontrolling interests	(5.5		)	—			—			—			—			(5.5		)
Balance at September 30, 2014	$	(85.8	)	$	(11.3	)	$	(123.6	)	$	12.5		$	(44.9	)	$	(253.1	)

Reclassifications out of accumulated other comprehensive income (expense) to the Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014:



(in millions)
Details about AOCI Components	Amounts Reclassified from AOCI						Affected Line Item in the Consolidated Statements of Operations
	Three Months Ended September 30,
	2015			2014

Gains and (losses) on derivative financial instruments:
Interest rate swaps	$	(1.1	)	$	(1.0	)	Interest expense
Foreign exchange forward contracts	3.8			(2.2		)	Cost of products sold
Foreign exchange forward contracts	0.1			—			SG&A expenses
	2.8			(3.2		)	Net gain (loss) before tax
	(0.2		)	1.3			Tax (expense) benefit
	$	2.6		$	(1.9	)	Net of tax

Net unrealized holding gain (loss) on available-for-sale securities:
Available-for-sale securities	$	(5.1	)	$	—		Other expense (income), net
	1.4			—			Tax expense
	$	(3.7	)	$	—		Net of tax

Amortization of defined benefit pension and other postemployment benefit items:
Amortization of prior service benefits	$	—		$	—		(a)
Amortization of net actuarial losses	(2.0		)	(0.7		)	(a)
	(2.0		)	(0.7		)	Net loss before tax
	0.6			0.2			Tax benefit
	$	(1.4	)	$	(0.5	)	Net of tax

Total reclassifications for the period	$	1.2		$	(2.4	)

(a) These accumulated other comprehensive income components are included in the computation of net periodic benefit cost for the three months ended September 30, 2015 and 2014 (see Note 8, Benefit Plans, for additional details).



(in millions)
Details about AOCI Components	Amounts Reclassified from AOCI						Affected Line Item in the Consolidated Statements of Operations
	Nine Months Ended September 30,
	2015			2014

Gains and (losses) on derivative financial instruments:
Interest rate swaps	$	(3.1	)	$	(2.8	)	Interest expense
Foreign exchange forward contracts	14.5			(5.5		)	Cost of products sold
Foreign exchange forward contracts	0.5			(0.2		)	SG&A expenses
Commodity contracts	(0.3		)	(0.5		)	Cost of products sold
	11.6			(9.0		)	Net gain (loss) before tax
	(0.8		)	3.0			Tax (expense) benefit
	$	10.8		$	(6.0	)	Net of tax

Net unrealized holding gain (loss) on available-for-sale securities:
Available-for-sale securities	$	(5.1	)	$	—		Other expense (income), net
	1.4			—			Tax expense
	$	(3.7	)	$	—		Net of tax

Amortization of defined benefit pension and other postemployment benefit items:
Amortization of prior service benefits	$	0.1		$	0.1		(a)
Amortization of net actuarial losses	(6.1		)	(2.1		)	(a)
	(6.0		)	(2.0		)	Net loss before tax
	1.7			0.6			Tax benefit
	$	(4.3	)	$	(1.4	)	Net of tax

Total reclassifications for the period	$	6.5		$	(7.4	)

(a) These accumulated other comprehensive income components are included in the computation of net periodic benefit cost for the nine months ended September 30, 2015 and 2014 (see Note 8, Benefit Plans, for additional details).

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

EARNINGS PER COMMON SHARE

9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

EARNINGS PER COMMON SHARE

The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2015 and 2014:



Basic Earnings Per Common Share Computation	Three Months Ended				Nine Months Ended
(in millions, except per share amounts)	2015		2014		2015		2014

Net income attributable to DENTSPLY International	$	84.5	$	75.3	$	192.6	$	238.1

Weighted average common shares outstanding	139.8		141.8		140.0		141.9

Earnings per common share - basic	$	0.60	$	0.53	$	1.38	$	1.68

Diluted Earnings Per Common Share Computation
(in millions, except per share amounts)

Net income attributable to DENTSPLY International	$	84.5	$	75.3	$	192.6	$	238.1

Weighted average common shares outstanding	139.8		141.8		140.0		141.9
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	2.6		2.5		2.5		2.4
Total weighted average diluted shares outstanding	142.4		144.3		142.5		144.3

Earnings per common share - diluted	$	0.59	$	0.52	$	1.35	$	1.65

The calculation of weighted average diluted common shares outstanding excludes stock options and RSU of 0.8 million and 1.0 million shares of common stock that were outstanding during the three and nine months ended September 30, 2015, respectively, because their effect would be antidilutive. There were 0.9 million and 1.2 million antidilutive shares of common stock outstanding during the three and nine months ended September 30, 2014, respectively.

BUSINESS COMBINATIONS	9 Months Ended
BUSINESS COMBINATIONS	Sep. 30, 2015
Business Combinations [Abstract]
BUSINESS COMBINATIONS	BUSINESS COMBINATIONS Effective January 1, 2014, the Company recorded a liability for the contractual purchase of the remaining shares of one variable interest entity. The Company paid this obligation during the first quarter of 2015. On September 15, 2015, the Company and Sirona Dental Systems, Inc. (“Sirona”) announced that the Board of Directors of both companies had unanimously approved a definitive Agreement and Plan of Merger (the “Merger Agreement”) under which the companies will combine in an all-stock merger of equals. Sirona develops, manufactures and markets several lines of dental products including CAD/CAM restoration systems, digital intra-oral, panoramic and 3D imaging systems, dental treatment centers and instruments. The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, a wholly-owned subsidiary of the Company will merge with and into Sirona, with Sirona surviving as a wholly-owned subsidiary of the Company. Upon completion of the merger, the Company's name will be changed to DENTSPLY SIRONA Inc. Subject to the terms and conditions of the Merger Agreement, if the merger is completed, each outstanding share of Sirona common stock will be converted into the right to receive 1.8142 shares of common stock of the Company, with cash paid in lieu of any fractional shares of common stock of the Company that a Sirona stockholder would otherwise have been entitled to receive. The Merger Agreement contains certain termination rights for both the Company and Sirona, including if the merger is not consummated on or before March 15, 2016 (which is subject to extension under certain circumstances but generally not beyond December 15, 2016) and if the approval of the stockholders of either the Company or Sirona is not obtained. The Merger Agreement further provides that, upon termination of the Merger Agreement under specified circumstances, including termination of the Merger Agreement by the Company or Sirona as a result of an adverse change in the recommendation of the other party’s board of directors, (i) the Company may be required to pay a termination fee of $280.0 million to Sirona and Sirona may be required to pay a termination fee of $205.0 million to the Company and (ii) either company may be required to reimburse the other company for merger-related expenses of up to $15.0 million. The transaction, which is expected to be completed in the first quarter of 2016, is subject to the receipt of regulatory approvals and other customary closing conditions, including the approval of shareholders of both DENTSPLY and Sirona. For additional information related to the merger refer to the Company's Registration Statement on Form S-4 which was filed with the SEC on October 29, 2015.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

SEGMENT AND GEOGRAPHIC INFORMATION

9 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

SEGMENT INFORMATION

The Company has numerous operating businesses covering a wide range of dental and certain healthcare products and geographic regions, primarily serving the professional dental market. Professional dental products represented approximately 88% of net sales for both the three and nine months ended September 30, 2015 and 2014.

The operating businesses are combined into operating groups, which generally have overlapping product offerings, geographical presence, customer bases, distribution channels, and regulatory oversight. These operating groups are considered the Company’s reportable segments as the Company’s chief operating decision-maker regularly reviews financial results at the operating group level and uses this information to manage the Company’s operations. The accounting policies of the segments are consistent with those described in the Company’s most recently filed Form 10-K, as revised on Form 8-K filed October 28, 2015, in the summary of significant accounting policies. The Company evaluates performance of the segments based on the groups’ net third party sales, excluding precious metal content, and segment income. The Company defines net third party sales excluding precious metal content as the Company’s net sales excluding the precious metal cost within the products sold, and this is considered a non-US GAAP measure. The Company’s exclusion of precious metal content in the measurement of net third party sales enhances comparability of performance between periods as it excludes the fluctuating market prices of the precious metal content. The Company defines segment income as net operating income after the assignment of certain direct corporate costs and before restructuring and other costs, interest expense, interest income, other expense (income), net and provision for income taxes. A description of the products and services provided within each of the Company’s three reportable segments is provided below.

Significant interdependencies exist among the Company’s operations in certain geographic areas. Inter-segment sales are at prices intended to provide a reasonable profit to the manufacturing unit after recovery of all manufacturing costs and to provide a reasonable profit for purchasing locations after coverage of marketing and general and administrative costs.

During the March 31, 2015 quarter, the Company realigned reporting responsibilities for multiple locations as a result of changes to the management structure. The segment information below reflects the revised structure for all periods shown.

Dental Consumables, Endodontic and Dental Laboratory Businesses

This segment includes responsibility for the design and manufacture of the Company’s chairside consumable products. It also has responsibilities for sales and distribution of certain small equipment and chairside consumable products in the United States, Germany and certain other European regions as well as responsibility for the sales and distribution of certain endodontic products in Germany and certain other European regions. In addition, this segment is responsible for the design, manufacture, sales and distribution of most of the Company’s dental laboratory products. This segment is also responsible for the design, manufacture, worldwide distribution and sales of certain non-dental products, excluding urological and surgery-related products.

Healthcare, Orthodontic and Implant Businesses

This segment is responsible for the worldwide design, manufacture, sales and distribution of the Company’s healthcare products, primarily urological and surgery-related products, throughout most of the world. This segment also includes responsibility for the design, manufacture, sales and distribution of orthodontic and implant products, in most regions of the world. Additionally, segment is also responsible for the sales and distribution of most of the Company’s other dental products, including most dental consumables within Canada.

Select Developed and Emerging Markets Businesses

This segment has responsibilities for sales and distribution of chairside consumable, endodontic and dental laboratory products within certain European regions, Japan and Australia. This segment also includes the responsibility for the sales and distribution of most of the Company’s dental products, including most dental consumables, sold in Eastern Europe, Middle East, South America, Latin America including Mexico, Asia and Africa.

The following tables set forth information about the Company’s segments for the three and nine months ended September 30, 2015 and 2014:

Third Party Net Sales



	Three Months Ended				Nine Months Ended
(in millions)	2015		2014		2015		2014

Dental Consumables, Endodontic and Dental Laboratory Businesses	$	306.4	$	323.7	$	934.0	$	1,009.2
Healthcare, Orthodontic and Implant Businesses	226.2		246.7		715.1		790.9
Select Developed and Emerging Markets Businesses	116.3		137.8		354.1		403.5
Total net sales	$	648.9	$	708.2	$	2,003.2	$	2,203.6

Third Party Net Sales, Excluding Precious Metal Content



	Three Months Ended				Nine Months Ended
(in millions)	2015		2014		2015		2014

Dental Consumables, Endodontic and Dental Laboratory Businesses	$	292.7	$	304.3	$	886.1	$	929.4
Healthcare, Orthodontic and Implant Businesses	226.1		246.6		714.6		790.3
Select Developed and Emerging Markets Businesses	110.5		130.7		334.9		382.0
Total net sales, excluding precious metal content	629.3		681.6		1,935.6		2,101.7
Precious metal content of sales	19.6		26.6		67.6		101.9
Total net sales, including precious metal content	$	648.9	$	708.2	$	2,003.2	$	2,203.6

Inter-segment Net Sales



	Three Months Ended						Nine Months Ended
(in millions)	2015			2014			2015			2014

Dental Consumables, Endodontic and Dental Laboratory Businesses	$	82.8		$	83.6		$	256.0		$	266.7
Healthcare, Orthodontic and Implant Businesses	2.0			1.2			5.3			5.7
Select Developed and Emerging Markets Businesses	3.4			3.4			9.7			9.7
All Other (a)	51.8			58.8			161.5			182.0
Eliminations	(140.0		)	(147.0		)	(432.5		)	(464.1		)
Total	$	—		$	—		$	—		$	—

(a) Includes amounts recorded at one distribution warehouse not managed by named segments.

Segment Operating Income (Loss)



	Three Months Ended						Nine Months Ended
(in millions)	2015			2014			2015			2014

Dental Consumables, Endodontic and Dental Laboratory Businesses	$	107.9		$	100.8		$	322.1		$	325.6
Healthcare, Orthodontic and Implant Businesses	28.0			26.9			82.5			83.5
Select Developed and Emerging Markets Businesses	(3.3		)	(1.7		)	(10.7		)	(4.2		)
Segment operating income	132.6			126.0			393.9			404.9

Reconciling Items (income) expense:
All Other (b)	27.4			13.9			60.9			58.1
Restructuring and other costs	6.6			2.5			50.9			4.5
Interest expense	9.6			12.7			30.1			35.4
Interest income	(0.4		)	(1.4		)	(1.8		)	(4.6		)
Other expense (income), net	(3.8		)	0.8			(3.6		)	1.8
Income before income taxes	$	93.2		$	97.5		$	257.4		$	309.7

(b) Includes the results of unassigned Corporate headquarter costs, inter-segment eliminations and one distribution warehouse not managed by named segments.

Assets



(in millions)	September 30, 2015		December 31, 2014

Dental Consumables, Endodontic and Dental Laboratory Businesses	$	1,333.9	$	1,358.0
Healthcare, Orthodontic and Implant Businesses	2,457.2		2,655.6
Select Developed and Emerging Markets Businesses	348.0		369.8
All Other (c)	263.1		263.1
Total	$	4,402.2	$	4,646.5

(c) Includes the assets of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

INVENTORIES

9 Months Ended

Sep. 30, 2015

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are stated at the lower of cost or market. The cost of inventories determined by the last-in, first-out (“LIFO”) method at September 30, 2015 and December 31, 2014 were $8.7 million and $6.3 million, respectively. The cost of other inventories was determined by the first-in, first-out (“FIFO”) or average cost methods. If the FIFO method had been used to determine the cost of LIFO inventories, the amounts at which net inventories are stated would be higher than reported at September 30, 2015 and December 31, 2014 by $6.4 million and $6.1 million, respectively.

Inventories, net of inventory valuation reserves, consist of the following:



(in millions)	September 30, 2015		December 31, 2014

Finished goods	$	236.9	$	253.3
Work-in-process	52.9		58.4
Raw materials and supplies	71.5		75.4
Inventories, net	$	361.3	$	387.1

The inventory valuation reserves were $37.6 million and $34.1 million at September 30, 2015 and December 31, 2014, respectively.

BENEFIT PLANS

9 Months Ended

Sep. 30, 2015

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]

BENEFIT PLANS

The following sets forth the components of net periodic benefit cost of the Company’s defined benefit plans and for the Company’s other postemployment benefit plans for the three and nine months ended September 30, 2015 and 2014:



Defined Benefit Plans	Three Months Ended						Nine Months Ended
(in millions)	2015			2014			2015			2014

Service cost	$	4.3		$	3.4		$	13.0		$	10.5
Interest cost	1.8			2.7			5.5			8.5
Expected return on plan assets	(1.3		)	(1.3		)	(4.1		)	(4.1		)
Amortization of prior service credit	—			—			(0.1		)	(0.1		)
Amortization of net actuarial loss	1.9			0.6			5.9			2.0
Net periodic benefit cost	$	6.7		$	5.4		$	20.2		$	16.8



Other Postemployment Benefit Plans	Three Months Ended				Nine Months Ended
(in millions)	2015		2014		2015		2014

Service cost	$	0.1	$	0.1	$	0.3	$	0.2
Interest cost	0.1		0.1		0.5		0.4
Amortization of net actuarial loss	0.1		—		0.1		—
Net periodic benefit cost	$	0.3	$	0.2	$	0.9	$	0.6

The following sets forth the information related to the contributions to the Company’s benefit plans for 2015:



(in millions)	Pension Benefits		Other Postemployment Benefits

Actual contributions through September 30, 2015	$	8.0	$	0.3
Projected contributions for the remainder of the year	3.5		0.3
Total projected contributions	$	11.5	$	0.6

RESTRUCTURING AND OTHER COSTS

9 Months Ended

Sep. 30, 2015

Restructuring and Related Activities [Abstract]

RESTRUCTURING AND OTHER COSTS

Restructuring Costs

During the three and nine months ended September 30, 2015, the Company recorded net restructuring costs and other costs of $6.6 million and $50.9 million, respectively. On May 22, 2015, the Company announced that it reorganized portions of its laboratory business and associated manufacturing capabilities within the Dental Consumables, Endodontics and Dental Laboratory Businesses segment. During the nine months ended September 2015 , the Company recorded $34.0 million of costs that consist primarily of employee severance benefits related to these and other similar actions. Also during the nine months ended September 30, 2015, the Company recorded restructuring costs of $10.2 million within the Healthcare, Orthodontic and Implant Businesses segment primarily related to the global efficiency initiative During the three and nine months ended September 30, 2014, the Company recorded net restructuring and other costs of $2.5 million and $4.5 million, respectively. These costs are recorded in “Restructuring and other costs” in the Consolidated Statements of Operations and the associated liabilities are recorded in “Accrued liabilities” in the Consolidated Balance Sheets.

At September 30, 2015, the Company’s restructuring accruals were as follows:



	Severance
(in millions)	2013 and Prior Plans			2014 Plans			2015 Plans			Total

Balance at December 31, 2014	$	0.9		$	5.1		$	—		$	6.0
Provisions	0.1			0.5			44.8			45.4
Amounts applied	(0.6		)	(3.4		)	(11.3		)	(15.3		)
Change in estimates	(0.1		)	(0.2		)	(1.3		)	(1.6		)
Balance at September 30, 2015	$	0.3		$	2.0		$	32.2		$	34.5



	Lease/Contract Terminations
(in millions)	2013 and Prior Plans			2014 Plans			2015 Plans			Total

Balance at December 31, 2014	$	0.5		$	1.7		$	—		$	2.2
Provisions	—			—			1.1			1.1
Amounts applied	(0.2		)	(0.5		)	(0.4		)	(1.1		)
Change in estimates	—			—			—			—
Balance at September 30, 2015	$	0.3		$	1.2		$	0.7		$	2.2



	Other Restructuring Costs
(in millions)	2013 and Prior Plans		2014 Plans			2015 Plans			Total

Balance at December 31, 2014	$	—	$	1.1		$	—		$	1.1
Provisions	—		0.2			2.6			2.8
Amounts applied	—		(0.8		)	(1.9		)	(2.7		)
Change in estimate	—		(0.1		)	—			(0.1		)
Balance at September 30, 2015	$	—	$	0.4		$	0.7		$	1.1

The following table provides the year-to-date changes in the restructuring accruals by segment:



(in millions)	December 31, 2014		Provisions		Amounts Applied			Change in Estimates			September 30, 2015

Dental Consumables, Endodontic and Dental Laboratory Businesses	$	5.3	$	34.7	$	(10.2	)	$	(1.0	)	$	28.8
Healthcare, Orthodontic and Implant Businesses	3.8		11.7		(8.1		)	(0.7		)	6.7
Select Developed and Emerging Markets Businesses	0.1		1.1		(0.4		)	—			0.8
All Other	0.1		1.8		(0.4		)	—			1.5
Total	$	9.3	$	49.3	$	(19.1	)	$	(1.7	)	$	37.8

FINANCIAL INSTRUMENTS AND DERIVATIVES

9 Months Ended

Sep. 30, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instrument and Derivatives

FINANCIAL INSTRUMENTS AND DERIVATIVES

Derivative Instruments and Hedging Activities

The Company’s activities expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates, interest rates and commodity prices. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company’s operating results and equity. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert variable rate debt to fixed rate debt and to convert fixed rate debt to variable rate debt, cross currency basis swaps to convert debt denominated in one currency to another currency and commodity swaps to fix certain variable raw material costs.

Derivative Instruments Designated as Hedging

Cash Flow Hedges

The following table summarizes the notional amounts of cash flow hedges by derivative instrument type at September 30, 2015 and the notional amounts expected to mature during the next 12 months, with a discussion of the various cash flow hedges by derivative instrument type following the table:



	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

(in millions)

Foreign exchange forward contracts	$	330.1	$	246.6
Interest rate swaps	171.3		66.7
Commodity contracts	1.2		1.0
Total derivative instruments designated as cash flow hedges	$	502.6	$	314.3

Foreign Exchange Risk Management

The Company uses a layered hedging program to hedge select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings of the consolidated Company. The Company accounts for the designated foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contracts primarily through AOCI based on the tested effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded in the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time value component of the fair value of the derivative is deemed ineffective and is reported currently in “Other expense (income), net” in the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in cash from operating activities in the Consolidated Statements of Cash Flows. The Company hedges various currencies, with the most significant activity occurring in euros, Swedish kronor, Canadian dollars, and Swiss francs.

These foreign exchange forward contracts generally have maturities up to 18 months and the counterparties to the transactions are typically large international financial institutions.

Interest Rate Risk Management

The Company uses interest rate swaps to convert a portion of its variable interest rate debt to fixed interest rate debt. At September 30, 2015, the Company has two significant exposures hedged with interest rate contracts. One exposure is hedged with derivative contracts having notional amounts totaling 12.6 billion Japanese yen, which effectively converts the underlying variable interest rate debt facility to a fixed interest rate of 0.2% for an initial term of five years ending September 2019. Another exposure hedged with derivative contracts has a notional amount of 65.0 million Swiss francs, and effectively converts the underlying variable interest rate of a Swiss franc denominated loan to a fixed interest rate of 0.7% for an initial term of five years, ending in September 2016.

The Company enters into interest rate swap contracts infrequently as they are only used to manage interest rate risk on long-term debt instruments and not for speculative purposes. Any cash flows associated with these instruments are included in cash from operating activities in the Consolidated Statements of Cash Flows.

Commodity Risk Management

The Company enters into precious metal commodity swap contracts to effectively fix certain variable raw material costs typically for up to 18 months. These swaps are used to stabilize the cost of components used in the production of certain products. The Company generally accounts for the commodity swaps as cash flow hedges. As a result, the Company records the fair value of the contracts primarily through AOCI based on the tested effectiveness of the commodity swaps. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded in the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time value component of the fair value of the derivative is deemed ineffective and is reported currently in “Interest expense” in the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in cash from operating activities in the Consolidated Statements of Cash Flows.

The following tables summarize the amount of gains (losses) recorded in AOCI in the Consolidated Balance Sheets and income (expense) in the Company’s Consolidated Statements of Operations related to all cash flow hedges for the three months ended September 30, 2015 and 2014:



September 30, 2015
	Gain (Loss) in AOCI			Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)			Ineffective Portion Recognized in Income (Expense)

(in millions)

Effective Portion:
Interest rate swaps	$	(0.1	)	Interest expense	$	(1.1	)	$	—
Foreign exchange forward contracts	(2.9		)	Cost of products sold	3.8			—
Foreign exchange forward contracts	—			SG&A expenses	0.1			—
Commodity contracts	(0.2		)	Cost of products sold	—			—

Ineffective Portion:
Foreign exchange forward contracts	—			Other expense (income), net	—			(0.5		)
Total in cash flow hedging	$	(3.2	)		$	2.8		$	(0.5	)



September 30, 2014
	Gain (Loss) in AOCI			Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)			Ineffective Portion Recognized in Income (Expense)

(in millions)

Effective Portion:
Interest rate swaps	$	0.3		Interest expense	$	(1.0	)	$	—
Foreign exchange forward contracts	7.5			Cost of products sold	(2.2		)	—
Foreign exchange forward contracts	0.3			SG&A expenses	—			—
Commodity contracts	(0.3		)	Cost of products sold	—			—

Ineffective Portion:
Foreign exchange forward contracts	—			Other expense (income), net	—			(1.0		)
Total for cash flow hedging	$	7.8			$	(3.2	)	$	(1.0	)



September 30, 2015
	Gain (Loss) in AOCI			Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)			Ineffective Portion Recognized in Income (Expense)

(in millions)

Effective Portion:
Interest rate swaps	$	(1.4	)	Interest expense	$	(3.1	)	$	—
Foreign exchange forward contracts	19.1			Cost of products sold	14.5			—
Foreign exchange forward contracts	0.3			SG&A expenses	0.5			—
Commodity contracts	(0.2		)	Cost of products sold	(0.3		)	—

Ineffective Portion:
Foreign exchange forward contracts	—			Other expense (income), net	—			(0.3		)
Total in cash flow hedging	$	17.8			$	11.6		$	(0.3	)



September 30, 2014
	Gain (Loss) in AOCI			Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)			Ineffective Portion Recognized in Income (Expense)

(in millions)

Effective Portion:
Interest rate swaps	$	(0.2	)	Interest expense	$	(2.8	)	$	—
Foreign exchange forward contracts	3.9			Cost of products sold	(5.5		)	—
Foreign exchange forward contracts	0.3			SG&A expenses	(0.2		)	—
Commodity contracts	(0.1		)	Cost of products sold	(0.5		)	—
Total for cash flow hedging	$	3.9			$	(9.0	)	$	—

Overall, the derivatives designated as cash flow hedges are considered to be highly effective. At September 30, 2015, the Company expects to reclassify $3.3 million of deferred net gains on cash flow hedges recorded in AOCI to the Consolidated Statements of Operations during the next 12 months. This reclassification is primarily due to the sale of inventory that includes hedged purchases and recognized interest expense on interest rate swaps. The term over which the Company is hedging exposures to variability of cash flows (for all forecasted transactions, excluding interest payments on variable interest rate debt) is typically 18 months.

For the rollforward of derivative instruments designated as cash flow hedges in AOCI see Note 3, Comprehensive Income.

Hedges of Net Investments in Foreign Operations

The Company has significant investments in foreign subsidiaries the most significant of which are denominated in euros, Swiss francs, Japanese yen and Swedish kronor. The net assets of these subsidiaries are exposed to volatility in currency exchange rates. The Company employs both derivative and non-derivative financial instruments to hedge a portion of this exposure . The derivative instruments consist of foreign exchange forward contracts and cross currency basis swaps. The non-derivative instruments consist of foreign currency denominated debt held at the parent company level. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in derivative and non-derivative financial instruments designated as hedges of net investments, which are included in AOCI. Any cash flows associated with these instruments are included in investing activities in the Consolidated Statements of Cash Flows except for derivative instruments that include an other-than-insignificant financing element, in which case all cash flows will be classified as financing activities in the Consolidated Statements of Cash Flows.

The following table summarizes the notional amounts of hedges of net investments by derivative instrument type at September 30, 2015 and the notional amounts expected to mature during the next 12 months:



	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

(in millions)

Foreign exchange forward contracts	$	409.9	$	226.2

The fair value of the cross currency basis swaps and foreign exchange forward contracts is the estimated amount the Company would receive or pay at the reporting date, taking into account the effective interest rates, cross currency swap basis rates and foreign exchange rates. The effective portion of the change in the value of these derivatives is recorded in AOCI, net of tax effects.

The following tables summarize the amount of gains (losses) recorded in AOCI in the Consolidated Balance Sheets and other income (expense) in the Company’s Consolidated Statements of Operations related to the hedges of net investments for the three months ended September 30, 2015 and 2014:



September 30, 2015
	Gain (Loss) in AOCI		Consolidated Statements of Operations Location	Recognized in Income (Expense)

(in millions)

Effective Portion:
Foreign exchange forward contracts	$	9.5	Other expense (income), net	$	2.0
Total for net investment hedging	$	9.5		$	2.0



September 30, 2014
	Gain (Loss) in AOCI		Consolidated Statements of Operations Location	Recognized in Income (Expense)

(in millions)

Effective Portion:
Cross currency basis swaps	$	22.4	Interest income	$	0.5
			Interest expense	(1.7		)
Foreign exchange forward contracts	21.2		Other expense (income), net	0.5
Total for net investment hedging	$	43.6		$	(0.7	)

The following table summarizes the amount of gains (losses) recorded in AOCI in the Consolidated Balance Sheets and other income (expense) in the Company’s Consolidated Statement of Operations related to the hedges of net investments for the nine months ended September 30, 2015 and 2014:



September 30, 2015
	Gain (Loss) in AOCI		Consolidated Statements of Operations Location	Recognized in Income (Expense)

(in millions)

Effective Portion:
Foreign exchange forward contracts	$	6.1	Other expense (income), net	$	2.8
Total for net investment hedging	$	6.1		$	2.8



September 30, 2014
	Gain (Loss) in AOCI		Consolidated Statements of Operations Location	Recognized in Income (Expense)

(in millions)

Effective Portion:
Cross currency basis swaps	$	19.3	Interest income	$	1.9
			Interest expense	(1.6		)
Foreign exchange forward contracts	25.5		Other expense (income), net	0.7
Total for net investment hedging	$	44.8		$	1.0

Fair Value Hedges

The Company uses interest rate swaps to convert a portion of its fixed interest rate debt to variable interest rate debt. The Company has U.S. dollar denominated interest rate swaps with an initial total notional value of $150.0 million to effectively convert the underlying fixed interest rate of 4.1% on the Company’s $250.0 million Private Placement Notes (“PPN”) to variable rate for an initial term of five years, ending February 2016. The notional value of the swaps will decline proportionately as portions of the PPN mature. These interest rate swaps are designated as fair value hedges of the interest rate risk associated with the hedged portion of the fixed rate PPN. Accordingly, the Company will carry the portion of the hedged debt at fair value, with the change in debt and swaps offsetting each other in the Consolidated Statements of Operations. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

The following table summarizes the notional amounts of fair value hedges by derivative instrument type at September 30, 2015 and the notional amounts expected to mature during the next 12 months:



	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

(in millions)

Interest rate swaps	$	45.0	$	45.0

The following tables summarize the amount of income (expense) recorded in the Company’s Consolidated Statements of Operations related to the hedges of fair value for the three and nine months ended September 30, 2015 and 2014:



	Consolidated Statements of Operations Location
		Three Months Ended September 30,					Nine Months Ended September 30,
(in millions)		2015		2014			2015		2014

Interest rate swaps	Interest expense	$	0.1	$	(0.1	)	$	0.2	$	0.1

Derivative Instruments Not Designated as Hedges

The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in “Other expense (income), net” in the Consolidated Statements of Operations. The Company primarily uses foreign exchange forward contracts and cross currency basis swaps to hedge these risks. Any cash flows associated with the foreign exchange forward contracts and interest rate swaps not designated as hedges are included in cash from operating activities in the Consolidated Statements of Cash Flows. Any cash flows associated with the cross currency basis swaps not designated as hedges are included in investing activities in the Consolidated Statements of Cash Flows except for derivative instruments that include an other-than-insignificant financing element, in which case the cash flows will be classified as financing activities in the Consolidated Statements of Cash Flows.

The following tables summarize the aggregate notional amounts of the Company’s economic hedges not designated as hedges by derivative instrument types at September 30, 2015 and the notional amounts expected to mature during the next 12 months:



	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

(in millions)

Foreign exchange forward contracts	$	428.5	$	423.3
Interest rate swaps	2.0		0.8
Total for instruments not designated as hedges	$	430.5	$	424.1

The Company had a Swiss franc denominated cross currency basis swaps to offset an intercompany Swiss franc note receivable at a U.S. dollar functional entity. The hedge matured during the second quarter of 2015 to coincide with the repayment of the note.

The following table summarizes the amounts of gains (losses) recorded in the Company’s Consolidated Statements of Operations related to the economic hedges not designated as hedging for the three and nine months ended September 30, 2015 and 2014:



	Consolidated Statements of Operations Location	Gain (Loss) Recognized
		Three Months Ended September 30,
(in millions)		2015			2014

Foreign exchange forward contracts (a)	Other expense (income), net	$	(4.1	)	$	36.8
Cross currency basis swaps (a)	Other expense (income), net	—			(40.6		)
Total for instruments not designated as hedges		$	(4.1	)	$	(3.8	)

(a) The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances which are recorded in “Other expense (income), net” in the Consolidated Statements of Operations.



	Consolidated Statements of Operations Location	Gain (Loss) Recognized
		Nine Months Ended September 30,
(in millions)		2015			2014

Foreign exchange forward contracts (a)	Other expense (income), net	$	3.7		$	31.6
DIO equity option contracts	Other expense (income), net	0.1			(0.2		)
Cross currency basis swaps (a)	Other expense (income), net	(1.8		)	(43.8		)
Total for instruments not designated as hedges		$	2.0		$	(12.4	)

Consolidated Balance Sheets Location of Derivative Fair Values

The following tables summarize the fair value and consolidated balance sheet location of the Company’s derivatives at September 30, 2015 and December 31, 2014:



	September 30, 2015
(in millions)	Prepaid Expenses and Other Current Assets, Net		Other Noncurrent Assets, Net		Accrued Liabilities		Other Noncurrent Liabilities
Designated as Hedges	Prepaid Expenses and Other Current Assets, Net		Other Noncurrent Assets, Net		Accrued Liabilities		Other Noncurrent Liabilities

Foreign exchange forward contracts	$	25.4	$	4.7	$	1.1	$	1.1
Commodity contracts	—		—		0.2		—
Interest rate swaps	0.2		—		1.4		0.1
Total	$	25.6	$	4.7	$	2.7	$	1.2

Not Designated as Hedges

Foreign exchange forward contracts	$	5.1	$	—	$	4.1	$	—
Total	$	5.1	$	—	$	4.1	$	—



	December 31, 2014
(in millions)	Prepaid Expenses and Other Current Assets, Net		Other Noncurrent Assets, Net		Accrued Liabilities		Other Noncurrent Liabilities
Designated as Hedges	Prepaid Expenses and Other Current Assets, Net		Other Noncurrent Assets, Net		Accrued Liabilities		Other Noncurrent Liabilities

Foreign exchange forward contracts	$	28.1	$	12.5	$	2.7	$	1.7
Commodity contracts	—		—		0.2		—
Interest rate swaps	0.6		0.1		0.6		0.4
Total	$	28.7	$	12.6	$	3.5	$	2.1

Not Designated as Hedges

Foreign exchange forward contracts	$	4.8	$	—	$	4.8	$	—
DIO equity option contracts	—		—		—		0.1
Interest rate swaps	—		—		—		0.1
Cross currency basis swaps	2.7		—		—		—
Total	$	7.5	$	—	$	4.8	$	0.2

Balance Sheet Offsetting

Substantially all of the Company’s derivative contracts are subject to netting arrangements, whereby the right to offset occurs in the event of default or termination in accordance with the terms of the arrangements with the counterparty. While these contracts contain the enforceable right to offset through netting arrangements with the same counterparty, the Company elects to present them on a gross basis in the Consolidated Balance Sheets.

Offsetting of financial assets and liabilities under netting arrangements at September 30, 2015:



							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments			Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	35.2	$	—	$	35.2	$	(7.6	)	$	—	$	27.6
Interest rate swaps	0.2		—		0.2		—			—		0.2
Total Assets	$	35.4	$	—	$	35.4	$	(7.6	)	$	—	$	27.8



							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments			Cash Collateral Received/Pledged		Net Amount

Liabilities
Foreign exchange forward contracts	$	6.2	$	—	$	6.2	$	(6.2	)	$	—	$	—
Commodity contracts	0.2		—		0.2		—			—		0.2
Interest rate swaps	1.6		—		1.6		(1.4		)	—		0.2
Total Liabilities	$	8.0	$	—	$	8.0	$	(7.6	)	$	—	$	0.4

Offsetting of financial assets and liabilities under netting arrangements at December 31, 2014:



							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments			Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	45.4	$	—	$	45.4	$	(7.8	)	$	—	$	37.6
Interest rate swaps	0.7		—		0.7		(0.2		)	—		0.5
Cross currency basis swaps	2.7		—		2.7		(1.1		)	—		1.6
Total Assets	$	48.8	$	—	$	48.8	$	(9.1	)	$	—	$	39.7



							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments			Cash Collateral Received/Pledged		Net Amount

Liabilities
Foreign exchange forward contracts	$	9.2	$	—	$	9.2	$	(8.2	)	$	—	$	1.0
Commodity contracts	0.2		—		0.2		—			—		0.2
DIO equity option contracts	0.1		—		0.1		—			—		0.1
Interest rate swaps	1.2		—		1.2		(1.0		)	—		0.2
Total Liabilities	$	10.7	$	—	$	10.7	$	(9.2	)	$	—	$	1.5

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

FAIR VALUE MEASUREMENT

9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENT

The Company records financial instruments at fair value with unrealized gains and losses related to certain financial instruments reflected in AOCI in the Consolidated Balance Sheets. In addition, the Company recognizes certain liabilities at fair value. The Company applies the market approach for recurring fair value measurements. Accordingly, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs.

The fair value of financial instruments is determined by reference to various market data and other valuation techniques as appropriate. The Company believes the carrying amounts of cash and cash equivalents, accounts receivable (net of allowance for doubtful accounts), prepaid expenses and other current assets, accounts payable, accrued liabilities, income taxes payable and notes payable approximate fair value due to the short-term nature of these instruments. The Company estimated the fair value and carrying value of total long-term debt, including the current portion, was $1,178.1 million and $1,152.0 million, respectively at September 30, 2015. At December 31, 2014, the Company estimated the fair value and carrying value, including the current portion, was $1,286.2 million and $1,258.9 million, respectively. The interest rate on the $450.0 million Senior Notes, the $300.0 million Senior Notes, and the $250.0 million PPN are fixed rates of 4.1%, 2.8% and 4.1%, respectively, and their fair value is based on the interest rates as of September 30, 2015. The interest rates on variable rate term loan debt and commercial paper are consistent with current market conditions, therefore the fair value of these instruments approximates their carrying values.

The following tables set forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis at September 30, 2015 and December 31, 2014, which are classified as “Cash and cash equivalents,” “Prepaid expenses and other current assets, net,” “Other noncurrent assets, net,” “Accrued liabilities,” and “Other noncurrent liabilities” in the Consolidated Balance Sheets. Financial assets and liabilities that are recorded at fair value as of the balance sheet date are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.



	September 30, 2015
(in millions)	Total		Level 1		Level 2		Level 3

Assets
Interest rate swaps	$	0.2	$	—	$	0.2	$	—
Foreign exchange forward contracts	35.2		—		35.2		—
Total assets	$	35.4	$	—	$	35.4	$	—

Liabilities
Interest rate swaps	$	1.6	$	—	$	1.6	$	—
Commodity contracts	0.2		—		0.2		—
Foreign exchange forward contracts	6.2		—		6.2		—
Long-term debt	45.2		—		45.2		—
Total liabilities	$	53.2	$	—	$	53.2	$	—



	December 31, 2014
(in millions)	Total		Level 1		Level 2		Level 3

Assets
Interest rate swaps	$	0.8	$	—	$	0.8	$	—
Cross currency basis swaps	2.7		—		2.7		—
Foreign exchange forward contracts	45.4		—		45.4		—
DIO Corporation convertible bonds	57.7		—		—		57.7
Total assets	$	106.6	$	—	$	48.9	$	57.7

Liabilities
Interest rate swaps	$	1.1	$	—	$	1.1	$	—
Commodity contracts	0.2		—		0.2		—
Foreign exchange forward contracts	9.2		—		9.2		—
Long-term debt	106.1		—		106.1		—
DIO equity option contracts	0.1		—		—		0.1
Total liabilities	$	116.7	$	—	$	116.6	$	0.1

Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates, future commodities prices and credit risks. As discussed in Note 10, Financial Instruments and Derivatives, commodity contracts, certain interest rate swaps and foreign exchange forward contracts are considered cash flow hedges. In addition, certain cross currency basis swaps and foreign exchange forward contracts are considered hedges of net investments in foreign operations.

The Company used the income method valuation technique to estimate the fair value of the DIO Corporation convertible bonds. The significant unobservable inputs for valuing the corporate bonds were both the DIO Corporation’s stock volatility factor of approximately 40% and corporate bond rating which implied approximately an 8.73% discount rate on the valuation model. Significant observable inputs used to value the corporate bonds included foreign exchange rates and DIO Corporation’s period-ending market stock price. During the three months ended September 30, 2015, the Company sold the DIO convertible bonds.

The following table presents a rollforward of the Company’s Level 3 holdings measured at fair value on a recurring basis using unobservable inputs:



(in millions)	DIO Corporation Convertible Bonds			DIO Equity Options Contracts

Balance at December 31, 2014	$	57.7		$	(0.1	)
Sales, gross	(47.7		)
Unrealized loss:
Reported in AOCI, pretax	(10.0		)	—
Realized gain:
Reported in other expense (income), net	—			0.1
Balance at September 30, 2015	$	—		$	—

For the three and nine months ended September 30, 2015, the Company sold all Level 3 investments. There were no additional purchases, issuances or transfers of Level 3 financial instruments in 2015.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Uncertainties in Income Taxes The Company recognizes in the interim consolidated financial statements, the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. It is reasonably possible that certain amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date of the Company’s interim consolidated financial statements. Final settlement and resolution of outstanding tax matters in various jurisdictions during the next twelve months could include unrecognized tax benefits of approximately $2.1 million. Of this total, approximately $0.7 million represents the amount of unrecognized tax benefits that, if recognized would affect the effective income tax rate. In addition, expiration of statutes of limitation in various jurisdictions during the next 12 months could include unrecognized tax benefits of approximately $0.4 million.

FINANCING ARRANGEMENTS	9 Months Ended
FINANCING ARRANGEMENTS	Sep. 30, 2015
Debt Disclosure [Abstract]
FINANCING ARRANGEMENTS	FINANCING ARRANGEMENTS During the quarter ended March 31, 2015, the Company paid the second required payment of $100.0 million under the Private Placement Notes “PPN” by issuing commercial paper at that time. The final required payment of $75.0 million due in February 2016 has been classified as current in the Consolidated Balance Sheets. During the quarter ended September 30, 2015, the Company paid the second required payment of $8.8 million under the PNC Term Loan. The third annual installment under the terms of the PNC Term Loan, in the amount of $8.8 million will be due in August 2016 has been classified as current in the Consolidated Balance Sheets. At September 30, 2015, there were no outstanding borrowings, in the form of issued commercial paper, under the current $500.0 million multi-currency revolving credit facility. Effective July 1, 2015, the Company amended the multi-currency revolving credit facility to extend the maturity date by one year until July 23, 2020. The Company is able to borrow up to $500.0 million through July 23, 2019 and up to $452.0 million through July 23, 2020. The Company’s revolving credit facility, term loans and PPN contain certain affirmative and negative covenants relating to the Company's operations and financial condition. At September 30, 2015, the Company was in compliance with all debt covenants. At September 30, 2015, the Company had $553.4 million of borrowing available under lines of credit, including lines available under its short-term arrangements and revolving credit agreement. On October 29, 2015, the Company announced the commencement of a tender offer to purchase for cash up to $150.0 million aggregate principle of its outstanding 4.125% Notes due August 2021. Concurrent with this tender offer, the Company intends to arrange new unsecured debt financing in an amount sufficient to fund the total consideration payable pursuant to the tender offer. The total consideration payable is estimated at $160.3 million, which includes the cost of the early tender premium under the existing note agreement and fees. Should the Company not be able to secure new debt financing sufficient to satisfy the tender offer, the Company intends to use available funds, borrowings available under lines of credit, including lines available under short term arrangements and revolving credit agreement.

GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

The Company performed the required annual impairment tests of goodwill as of April 30, 2015 on 16 reporting units. As discussed in Note 6, Segment Information, effective in the first quarter of 2015, the Company realigned reporting responsibilities for multiple locations. For any realignment that resulted in reporting unit changes, the Company applied the relative fair value method to determine the reallocation of goodwill of the associated reporting units.

To determine the fair value of the Company’s reporting units, the Company uses a discounted cash flow model with market-based support as its valuation technique to measure the fair value for its reporting units. The discounted cash flow model uses five-year forecasted cash flows plus a terminal value based on a multiple of earnings. In addition, the Company applies gross margin and operating expense assumptions consistent with historical trends. The total cash flows were discounted based on a range between 7.6% to 12.5%, which included assumptions regarding the Company’s weighted-average cost of capital. The Company considered the current market conditions both in the U.S. and globally, when determining its assumptions. Lastly, the Company reconciled the aggregated fair values of its reporting units to its market capitalization, which included a reasonable control premium based on market conditions. As a result of the annual impairment tests of goodwill, no impairment was identified.

In addition, the Company assessed the annual impairment of indefinite-lived intangible assets as of April 30, 2015, which largely consists of acquired tradenames, in conjunction with the annual impairment tests of goodwill. The performance of the Company’s annual impairment test did not result in any impairment of the Company’s indefinite-lived assets.

A reconciliation of changes in the Company’s goodwill is as follows:



(in millions)	Dental Consumables, Endodontic and Dental Laboratory Businesses			Healthcare, Orthodontic and Implant Businesses			Select Developed and Emerging Markets Businesses			Total

Balance at December 31, 2014	$	565.7		$	1,394.4		$	129.2		$	2,089.3
Effects of exchange rate changes	(6.5		)	(86.4		)	(12.1		)	(105.0		)
Balance at September 30, 2015	$	559.2		$	1,308.0		$	117.1		$	1,984.3

Identifiable definite-lived and indefinite-lived intangible assets consist of the following:



	September 30, 2015							December 31, 2014
(in millions)	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount

Patents	$	165.3	$	(93.2	)	$	72.1	$	175.2	$	(95.5	)	$	79.7
Trademarks	64.1		(35.1		)	29.0		75.6		(37.1		)	38.5
Licensing agreements	34.0		(24.4		)	9.6		34.6		(22.8		)	11.8
Customer relationships	429.7		(120.2		)	309.5		452.9		(104.7		)	348.2
Total definite-lived	$	693.1	$	(272.9	)	$	420.2	$	738.3	$	(260.1	)	$	478.2

Indefinite-lived Trademarks and In-process R&D	$	180.2	$	—		$	180.2	$	192.6	$	—		$	192.6

Total identifiable intangible assets	$	873.3	$	(272.9	)	$	600.4	$	930.9	$	(260.1	)	$	670.8

During the nine months ended September 30, 2015, the Company impaired a trademark for $3.7 million that was held in the Dental Consumable, Endodontics and Dental Laboratory Businesses segment which was recorded in “Restructuring and other costs” in the Consolidated Statements of Operations.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation On June 18, 2004, Marvin Weinstat, DDS and Richard Nathan, DDS filed a class action suit in San Francisco County, California alleging that the Company misrepresented that its Cavitron® ultrasonic scalers are suitable for use in oral surgical procedures. The Complaint seeks a recall of the product and refund of its purchase price to dentists who have purchased it for use in oral surgery. The Court certified the case as a class action in June 2006 with respect to the breach of warranty and unfair business practices claims. The class that was certified is defined as California dental professionals who, at any time during the period beginning June 18, 2000 through September 14, 2012, purchased and used one or more Cavitron® ultrasonic scalers for the performance of oral surgical procedures on their patients, which Cavitrons® were accompanied by Directions for Use that “Indicated” Cavitron® use for “periodontal debridement for all types of periodontal disease.” The case went to trial in September 2013, and on January 22, 2014, the San Francisco Superior Court issued its decision in the Company’s favor, rejecting all of the plaintiffs’ claims. The plaintiffs have appealed the Superior Court’s decision, and the appeal is now pending. The Company is defending against this appeal. On December 12, 2006, a Complaint was filed by Carole Hildebrand, DDS and Robert Jaffin, DDS in the Eastern District of Pennsylvania (the Plaintiffs subsequently added Dr. Mitchell Goldman as a named class representative). The case was filed by the same law firm that filed the Weinstat case in California. The Complaint asserts putative class action claims on behalf of dentists located in New Jersey and Pennsylvania. The Complaint seeks damages and asserts that the Company’s Cavitron® ultrasonic scaler was negligently designed and sold in breach of contract and warranty arising from misrepresentations about the potential uses of the product because it cannot assure the delivery of potable or sterile water. Following grant of a Company Motion and dismissal of the case for lack of jurisdiction, the plaintiffs filed a second complaint under the name of Dr. Hildebrand’s corporate practice, Center City Periodontists, asserting the same allegations (this case is now proceeding under the name “Center City Periodontists”). The plaintiffs moved to have the case certified as a class action, to which the Company has objected and filed its brief. The Court subsequently granted a Motion filed by the Company and dismissed plaintiffs’ New Jersey Consumer Fraud and negligent design claims, leaving only a breach of express warranty claim, in response to which the Company has filed a Motion for Summary Judgment. The Court has rescheduled a hearing to January 2016 on plaintiffs’ class certification motion. On January 20, 2014, the Company was served with a qui tam complaint filed by two former and one current employee of the Company under the Federal False Claims Act and equivalent state and city laws. The lawsuit was previously under seal in the U.S. District Court for the Eastern District of Pennsylvania. The complaint alleges, among other things, that the Company engaged in various illegal marketing activities, and thereby caused dental and other healthcare professionals to file false claims for reimbursement with Federal and State governments. The relators seek injunctive relief, fines, treble damages, and attorneys’ fees and costs. On January 27, 2014, the United States filed with the Court a notice that it had elected not to intervene in the qui tam action at this time. The United States’ notice indicated that the named state and city co-plaintiffs had authorized the United States to communicate to the Court that they also had decided not to intervene at this time. These non-intervention decisions do not prevent the qui tam relators from litigating this action, and the United States and/or the named states and/or cities may seek to intervene in the action at a later time. On September 4, 2014, the Company’s motion to dismiss the complaint was granted in part and denied in part. The Company intends to vigorously defend itself in the litigation. On October 2, 2015 and October 5, 2015, the Company and its wholly-owned subsidiary Dawkins Merger Sub Inc. (“Merger Sub”) were served with two separate putative class action complaints filed in the Court of Chancery of the State of Delaware by purported stockholders of Sirona Dental Systems, Inc. (“Sirona”) against the members of Sirona’s Board of Directors, the Company, and Merger Sub. The complaints allege that the Company and Merger Sub aided and abetted and/or assisted Sirona’s Board members in breaching their fiduciary duties to Sirona’s stockholders in connection with the Agreement and Plan of Merger entered into between the Company and Sirona on September 15, 2015. The Company intends to vigorously defend itself in this litigation. The Company does not believe a loss is probable related to the above litigation. Further a reasonable estimate of a possible range of loss cannot be made. In the event that one or more of these matters is unfavorably resolved, it is possible the Company’s results from operations could be materially impacted. In 2012, the Company received subpoenas from the United States Attorney’s Office for the Southern District of Indiana (the “USAO”) and from the Office of Foreign Assets Control of the United States Department of the Treasury (“OFAC”) requesting documents and information related to compliance with export controls and economic sanctions regulations by certain of its subsidiaries. The Company has voluntarily contacted OFAC and the Bureau of Industry and Security of the United States Department of Commerce (“BIS”), in connection with these matters as well as regarding compliance with export controls and economic sanctions regulations by certain other business units of the Company identified in connection with an internal review by the Company. On August 24, 2015, the Company entered into an extension of the tolling agreement originally entered into in August 2014, such that the statute of limitations is now tolled until September 1, 2016. The Company is cooperating with the USAO, OFAC and BIS with respect to these matters. At this stage of the inquiries, the Company is unable to predict the ultimate outcome of these matters or what impact, if any, the outcome of these matters might have on the Company’s consolidated financial position, results of operations or cash flows. Violations of export control or economic sanctions laws or regulations could result in a range of governmental enforcement actions, including fines or penalties, injunctions and/or criminal or other civil proceedings, which actions could have a material adverse effect on the Company’s reputation, business, financial condition and results of operations. At this time, no claims have been made against the Company. In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company’s products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition and sales and trading practices, personal injury and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory damages. Based upon the Company’s experience, current information and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity. While the Company maintains general, products, property, workers’ compensation, automobile, cargo, aviation, crime, fiduciary and directors’ and officers’ liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses. Purchase Commitments From time to time, the Company enters into long-term inventory purchase commitments with minimum purchase requirements for raw materials and finished goods to ensure the availability of products for production and distribution. These commitments may have a significant impact on levels of inventory maintained by the Company.

SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Accounts and Notes Receivable-Trade

The Company records a provision for doubtful accounts, which is included in “Selling, general and administrative expenses” in the Consolidated Statements of Operations.

New Accounting Pronouncements, Policy



December 31, 2014
(in millions)	As Reported
Consolidated Balance Sheet Line Item	Balance		Adjustment			Adjusted Balance
Other noncurrent assets, net	$	94.3	$	(3.8	)	$	90.5
Notes payable and current portion of long-term debt	112.8		(1.0		)	111.8
Long-term debt	1,152.9		(2.8		)	1,150.1



March 31, 2015
(in millions)	As Reported
Consolidated Balance Sheet Line Item	Balance		Adjustment			Adjusted Balance
Other noncurrent assets, net	$	61.3	$	(3.6	)	$	57.7
Notes payable and current portion of long-term debt	247.6		(0.9		)	246.7
Long-term debt	1,078.8		(2.6		)	1,076.2

Description of New Accounting Pronouncements Not yet Adopted



December 31, 2014
(in millions)	As Reported
Consolidated Balance Sheet Line Item	Balance		Adjustment			Adjusted Balance
Other noncurrent assets, net	$	94.3	$	(3.8	)	$	90.5
Notes payable and current portion of long-term debt	112.8		(1.0		)	111.8
Long-term debt	1,152.9		(2.8		)	1,150.1



March 31, 2015
(in millions)	As Reported
Consolidated Balance Sheet Line Item	Balance		Adjustment			Adjusted Balance
Other noncurrent assets, net	$	61.3	$	(3.6	)	$	57.7
Notes payable and current portion of long-term debt	247.6		(0.9		)	246.7
Long-term debt	1,078.8		(2.6		)	1,076.2

SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

New Accounting Pronouncement, Early Adoption

The following is a summary of the adjustment to the financial statement line items impacted by this accounting update:



December 31, 2014
(in millions)	As Reported
Consolidated Balance Sheet Line Item	Balance		Adjustment			Adjusted Balance
Other noncurrent assets, net	$	94.3	$	(3.8	)	$	90.5
Notes payable and current portion of long-term debt	112.8		(1.0		)	111.8
Long-term debt	1,152.9		(2.8		)	1,150.1



March 31, 2015
(in millions)	As Reported
Consolidated Balance Sheet Line Item	Balance		Adjustment			Adjusted Balance
Other noncurrent assets, net	$	61.3	$	(3.6	)	$	57.7
Notes payable and current portion of long-term debt	247.6		(0.9		)	246.7
Long-term debt	1,078.8		(2.6		)	1,076.2

Stock Compensation (Tables)

9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock Based Compensation



	Three Months Ended				Nine Months Ended
(in millions)	2015		2014		2015		2014

Stock option expense	$	2.3	$	2.2	$	6.0	$	6.6
RSU expense	5.1		4.0		12.5		12.1
Total stock based compensation expense	$	7.4	$	6.2	$	18.5	$	18.7

Total related tax benefit	$	2.1	$	1.6	$	5.5	$	5.1

Comprehensive Income (Tables)

9 Months Ended

Sep. 30, 2015

COMPREHENSIVE INCOME [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in AOCI, net of tax, by component for the nine months ended September 30, 2015 and 2014:



(in millions)	Foreign Currency Translation Adjustments			Gain and (Loss) on Derivative Financial Instruments Designated as Cash Flow Hedges			Gain and (Loss) on Derivative Financial Instruments Designated as Net Investment Hedges			Net Unrealized Holding Gain (Loss) on Available-for-Sale Securities			Pension Liability Adjustments			Total

Balance at December 31, 2014	$	(212.5	)	$	(10.8	)	$	(112.7	)	$	8.5		$	(113.6	)	$	(441.1	)
Other comprehensive income (loss) before reclassifications	(151.2		)	15.4			4.4			(4.8		)	—			(136.2		)
Amounts reclassified from accumulated other comprehensive income (loss)	—			(10.8		)	—			(3.7		)	4.3			(10.2		)
Net (decrease) increase in other comprehensive income	(151.2		)	4.6			4.4			(8.5		)	4.3			(146.4		)

Balance at September 30, 2015	$	(363.7	)	$	(6.2	)	$	(108.3	)	$	—		$	(109.3	)	$	(587.5	)



(in millions)	Foreign Currency Translation Adjustments			Gain and (Loss) on Derivative Financial Instruments Designated as Cash Flow Hedges			Gain and (Loss) on Derivative Financial Instruments Designated as Net Investment Hedges			Net Unrealized Holding Gain (Loss)on Available-for-Sale Securities			Pension Liability Adjustments			Total

Balance at December 31, 2013	$	141.0		$	(21.8	)	$	(151.1	)	$	12.7		$	(49.9	)	$	(69.1	)
Other comprehensive income (loss) before reclassifications	(221.3		)	4.5			27.5			(0.2		)	3.6			(185.9		)
Amounts reclassified from accumulated other comprehensive income (loss)	—			6.0			—			—			1.4			7.4
Net (decrease) increase in other comprehensive income	(221.3		)	10.5			27.5			(0.2		)	5.0			(178.5		)
Foreign currency translation related to acquisition of noncontrolling interests	(5.5		)	—			—			—			—			(5.5		)
Balance at September 30, 2014	$	(85.8	)	$	(11.3	)	$	(123.6	)	$	12.5		$	(44.9	)	$	(253.1	)

Reclassification out of Accumulated Other Comprehensive Income

Reclassifications out of accumulated other comprehensive income (expense) to the Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014:



(in millions)
Details about AOCI Components	Amounts Reclassified from AOCI						Affected Line Item in the Consolidated Statements of Operations
	Three Months Ended September 30,
	2015			2014

Gains and (losses) on derivative financial instruments:
Interest rate swaps	$	(1.1	)	$	(1.0	)	Interest expense
Foreign exchange forward contracts	3.8			(2.2		)	Cost of products sold
Foreign exchange forward contracts	0.1			—			SG&A expenses
	2.8			(3.2		)	Net gain (loss) before tax
	(0.2		)	1.3			Tax (expense) benefit
	$	2.6		$	(1.9	)	Net of tax

Net unrealized holding gain (loss) on available-for-sale securities:
Available-for-sale securities	$	(5.1	)	$	—		Other expense (income), net
	1.4			—			Tax expense
	$	(3.7	)	$	—		Net of tax

Amortization of defined benefit pension and other postemployment benefit items:
Amortization of prior service benefits	$	—		$	—		(a)
Amortization of net actuarial losses	(2.0		)	(0.7		)	(a)
	(2.0		)	(0.7		)	Net loss before tax
	0.6			0.2			Tax benefit
	$	(1.4	)	$	(0.5	)	Net of tax

Total reclassifications for the period	$	1.2		$	(2.4	)

EARNINGS PER COMMON SHARE (Tables)

9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Common Share

The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2015 and 2014:



Basic Earnings Per Common Share Computation	Three Months Ended				Nine Months Ended
(in millions, except per share amounts)	2015		2014		2015		2014

Net income attributable to DENTSPLY International	$	84.5	$	75.3	$	192.6	$	238.1

Weighted average common shares outstanding	139.8		141.8		140.0		141.9

Earnings per common share - basic	$	0.60	$	0.53	$	1.38	$	1.68

Diluted Earnings Per Common Share Computation
(in millions, except per share amounts)

Net income attributable to DENTSPLY International	$	84.5	$	75.3	$	192.6	$	238.1

Weighted average common shares outstanding	139.8		141.8		140.0		141.9
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	2.6		2.5		2.5		2.4
Total weighted average diluted shares outstanding	142.4		144.3		142.5		144.3

Earnings per common share - diluted	$	0.59	$	0.52	$	1.35	$	1.65

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)

9 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

Net Sales

The following tables set forth information about the Company’s segments for the three and nine months ended September 30, 2015 and 2014:

Third Party Net Sales



	Three Months Ended				Nine Months Ended
(in millions)	2015		2014		2015		2014

Dental Consumables, Endodontic and Dental Laboratory Businesses	$	306.4	$	323.7	$	934.0	$	1,009.2
Healthcare, Orthodontic and Implant Businesses	226.2		246.7		715.1		790.9
Select Developed and Emerging Markets Businesses	116.3		137.8		354.1		403.5
Total net sales	$	648.9	$	708.2	$	2,003.2	$	2,203.6

Net Sales, Excluding Precious Metal Content

Third Party Net Sales, Excluding Precious Metal Content



	Three Months Ended				Nine Months Ended
(in millions)	2015		2014		2015		2014

Dental Consumables, Endodontic and Dental Laboratory Businesses	$	292.7	$	304.3	$	886.1	$	929.4
Healthcare, Orthodontic and Implant Businesses	226.1		246.6		714.6		790.3
Select Developed and Emerging Markets Businesses	110.5		130.7		334.9		382.0
Total net sales, excluding precious metal content	629.3		681.6		1,935.6		2,101.7
Precious metal content of sales	19.6		26.6		67.6		101.9
Total net sales, including precious metal content	$	648.9	$	708.2	$	2,003.2	$	2,203.6

Intersegment Net Sales

Inter-segment Net Sales



	Three Months Ended						Nine Months Ended
(in millions)	2015			2014			2015			2014

Dental Consumables, Endodontic and Dental Laboratory Businesses	$	82.8		$	83.6		$	256.0		$	266.7
Healthcare, Orthodontic and Implant Businesses	2.0			1.2			5.3			5.7
Select Developed and Emerging Markets Businesses	3.4			3.4			9.7			9.7
All Other (a)	51.8			58.8			161.5			182.0
Eliminations	(140.0		)	(147.0		)	(432.5		)	(464.1		)
Total	$	—		$	—		$	—		$	—

(a) Includes amounts recorded at one distribution warehouse not managed by named segments.

Segment Operating Income

Segment Operating Income (Loss)



	Three Months Ended						Nine Months Ended
(in millions)	2015			2014			2015			2014

Dental Consumables, Endodontic and Dental Laboratory Businesses	$	107.9		$	100.8		$	322.1		$	325.6
Healthcare, Orthodontic and Implant Businesses	28.0			26.9			82.5			83.5
Select Developed and Emerging Markets Businesses	(3.3		)	(1.7		)	(10.7		)	(4.2		)
Segment operating income	132.6			126.0			393.9			404.9

Reconciling Items (income) expense:
All Other (b)	27.4			13.9			60.9			58.1
Restructuring and other costs	6.6			2.5			50.9			4.5
Interest expense	9.6			12.7			30.1			35.4
Interest income	(0.4		)	(1.4		)	(1.8		)	(4.6		)
Other expense (income), net	(3.8		)	0.8			(3.6		)	1.8
Income before income taxes	$	93.2		$	97.5		$	257.4		$	309.7

(b) Includes the results of unassigned Corporate headquarter costs, inter-segment eliminations and one distribution warehouse not managed by named segments.

Assets



(in millions)	September 30, 2015		December 31, 2014

Dental Consumables, Endodontic and Dental Laboratory Businesses	$	1,333.9	$	1,358.0
Healthcare, Orthodontic and Implant Businesses	2,457.2		2,655.6
Select Developed and Emerging Markets Businesses	348.0		369.8
All Other (c)	263.1		263.1
Total	$	4,402.2	$	4,646.5

(c) Includes the assets of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.

INVENTORIES (Tables)

9 Months Ended

Sep. 30, 2015

Inventory Disclosure [Abstract]

Inventories, net

Inventories, net of inventory valuation reserves, consist of the following:



(in millions)	September 30, 2015		December 31, 2014

Finished goods	$	236.9	$	253.3
Work-in-process	52.9		58.4
Raw materials and supplies	71.5		75.4
Inventories, net	$	361.3	$	387.1

BENEFIT PLANS (Tables)

9 Months Ended

Sep. 30, 2015

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]

Components of Net Periodic Benefit Cost



Defined Benefit Plans	Three Months Ended						Nine Months Ended
(in millions)	2015			2014			2015			2014

Service cost	$	4.3		$	3.4		$	13.0		$	10.5
Interest cost	1.8			2.7			5.5			8.5
Expected return on plan assets	(1.3		)	(1.3		)	(4.1		)	(4.1		)
Amortization of prior service credit	—			—			(0.1		)	(0.1		)
Amortization of net actuarial loss	1.9			0.6			5.9			2.0
Net periodic benefit cost	$	6.7		$	5.4		$	20.2		$	16.8



Other Postemployment Benefit Plans	Three Months Ended				Nine Months Ended
(in millions)	2015		2014		2015		2014

Service cost	$	0.1	$	0.1	$	0.3	$	0.2
Interest cost	0.1		0.1		0.5		0.4
Amortization of net actuarial loss	0.1		—		0.1		—
Net periodic benefit cost	$	0.3	$	0.2	$	0.9	$	0.6

The following sets forth the information related to the contributions to the Company’s benefit plans for 2015:



(in millions)	Pension Benefits		Other Postemployment Benefits

Actual contributions through September 30, 2015	$	8.0	$	0.3
Projected contributions for the remainder of the year	3.5		0.3
Total projected contributions	$	11.5	$	0.6

RESTRUCTURING AND OTHER COSTS (Tables)

9 Months Ended

Sep. 30, 2015

Restructuring and Related Activities [Abstract]

Restructuring Accruals

At September 30, 2015, the Company’s restructuring accruals were as follows:



	Severance
(in millions)	2013 and Prior Plans			2014 Plans			2015 Plans			Total

Balance at December 31, 2014	$	0.9		$	5.1		$	—		$	6.0
Provisions	0.1			0.5			44.8			45.4
Amounts applied	(0.6		)	(3.4		)	(11.3		)	(15.3		)
Change in estimates	(0.1		)	(0.2		)	(1.3		)	(1.6		)
Balance at September 30, 2015	$	0.3		$	2.0		$	32.2		$	34.5



	Lease/Contract Terminations
(in millions)	2013 and Prior Plans			2014 Plans			2015 Plans			Total

Balance at December 31, 2014	$	0.5		$	1.7		$	—		$	2.2
Provisions	—			—			1.1			1.1
Amounts applied	(0.2		)	(0.5		)	(0.4		)	(1.1		)
Change in estimates	—			—			—			—
Balance at September 30, 2015	$	0.3		$	1.2		$	0.7		$	2.2



	Other Restructuring Costs
(in millions)	2013 and Prior Plans		2014 Plans			2015 Plans			Total

Balance at December 31, 2014	$	—	$	1.1		$	—		$	1.1
Provisions	—		0.2			2.6			2.8
Amounts applied	—		(0.8		)	(1.9		)	(2.7		)
Change in estimate	—		(0.1		)	—			(0.1		)
Balance at September 30, 2015	$	—	$	0.4		$	0.7		$	1.1

Cumulative Amounts for the Provisions and Adjustments and Amounts Applied for All the Plans by Segment

The following table provides the year-to-date changes in the restructuring accruals by segment:



(in millions)	December 31, 2014		Provisions		Amounts Applied			Change in Estimates			September 30, 2015

Dental Consumables, Endodontic and Dental Laboratory Businesses	$	5.3	$	34.7	$	(10.2	)	$	(1.0	)	$	28.8
Healthcare, Orthodontic and Implant Businesses	3.8		11.7		(8.1		)	(0.7		)	6.7
Select Developed and Emerging Markets Businesses	0.1		1.1		(0.4		)	—			0.8
All Other	0.1		1.8		(0.4		)	—			1.5
Total	$	9.3	$	49.3	$	(19.1	)	$	(1.7	)	$	37.8

Derivative Instruments and Hedging Activities (Tables)

9 Months Ended

Sep. 30, 2015

Derivative [Line Items]

Schedule of Derivative Instruments



	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

(in millions)

Foreign exchange forward contracts	$	409.9	$	226.2



	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

(in millions)

Foreign exchange forward contracts	$	330.1	$	246.6
Interest rate swaps	171.3		66.7
Commodity contracts	1.2		1.0
Total derivative instruments designated as cash flow hedges	$	502.6	$	314.3

Derivative Instruments, Gain (Loss)



	Consolidated Statements of Operations Location	Gain (Loss) Recognized
		Three Months Ended September 30,
(in millions)		2015			2014

Foreign exchange forward contracts (a)	Other expense (income), net	$	(4.1	)	$	36.8
Cross currency basis swaps (a)	Other expense (income), net	—			(40.6		)
Total for instruments not designated as hedges		$	(4.1	)	$	(3.8	)

Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]



	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

(in millions)

Foreign exchange forward contracts	$	428.5	$	423.3
Interest rate swaps	2.0		0.8
Total for instruments not designated as hedges	$	430.5	$	424.1

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The following tables summarize the fair value and consolidated balance sheet location of the Company’s derivatives at September 30, 2015 and December 31, 2014:



	September 30, 2015
(in millions)	Prepaid Expenses and Other Current Assets, Net		Other Noncurrent Assets, Net		Accrued Liabilities		Other Noncurrent Liabilities
Designated as Hedges	Prepaid Expenses and Other Current Assets, Net		Other Noncurrent Assets, Net		Accrued Liabilities		Other Noncurrent Liabilities

Foreign exchange forward contracts	$	25.4	$	4.7	$	1.1	$	1.1
Commodity contracts	—		—		0.2		—
Interest rate swaps	0.2		—		1.4		0.1
Total	$	25.6	$	4.7	$	2.7	$	1.2

Not Designated as Hedges

Foreign exchange forward contracts	$	5.1	$	—	$	4.1	$	—
Total	$	5.1	$	—	$	4.1	$	—



	December 31, 2014
(in millions)	Prepaid Expenses and Other Current Assets, Net		Other Noncurrent Assets, Net		Accrued Liabilities		Other Noncurrent Liabilities
Designated as Hedges	Prepaid Expenses and Other Current Assets, Net		Other Noncurrent Assets, Net		Accrued Liabilities		Other Noncurrent Liabilities

Foreign exchange forward contracts	$	28.1	$	12.5	$	2.7	$	1.7
Commodity contracts	—		—		0.2		—
Interest rate swaps	0.6		0.1		0.6		0.4
Total	$	28.7	$	12.6	$	3.5	$	2.1

Not Designated as Hedges

Foreign exchange forward contracts	$	4.8	$	—	$	4.8	$	—
DIO equity option contracts	—		—		—		0.1
Interest rate swaps	—		—		—		0.1
Cross currency basis swaps	2.7		—		—		—
Total	$	7.5	$	—	$	4.8	$	0.2

Offsetting Derivative Assets and Liabilities

Offsetting of financial assets and liabilities under netting arrangements at September 30, 2015:



							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments			Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	35.2	$	—	$	35.2	$	(7.6	)	$	—	$	27.6
Interest rate swaps	0.2		—		0.2		—			—		0.2
Total Assets	$	35.4	$	—	$	35.4	$	(7.6	)	$	—	$	27.8



							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments			Cash Collateral Received/Pledged		Net Amount

Liabilities
Foreign exchange forward contracts	$	6.2	$	—	$	6.2	$	(6.2	)	$	—	$	—
Commodity contracts	0.2		—		0.2		—			—		0.2
Interest rate swaps	1.6		—		1.6		(1.4		)	—		0.2
Total Liabilities	$	8.0	$	—	$	8.0	$	(7.6	)	$	—	$	0.4

Offsetting of financial assets and liabilities under netting arrangements at December 31, 2014:



							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments			Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	45.4	$	—	$	45.4	$	(7.8	)	$	—	$	37.6
Interest rate swaps	0.7		—		0.7		(0.2		)	—		0.5
Cross currency basis swaps	2.7		—		2.7		(1.1		)	—		1.6
Total Assets	$	48.8	$	—	$	48.8	$	(9.1	)	$	—	$	39.7



							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments			Cash Collateral Received/Pledged		Net Amount

Liabilities
Foreign exchange forward contracts	$	9.2	$	—	$	9.2	$	(8.2	)	$	—	$	1.0
Commodity contracts	0.2		—		0.2		—			—		0.2
DIO equity option contracts	0.1		—		0.1		—			—		0.1
Interest rate swaps	1.2		—		1.2		(1.0		)	—		0.2
Total Liabilities	$	10.7	$	—	$	10.7	$	(9.2	)	$	—	$	1.5

Cash Flow Hedging

Derivative [Line Items]

Schedule of Derivative Instruments



September 30, 2015
	Gain (Loss) in AOCI			Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)			Ineffective Portion Recognized in Income (Expense)

(in millions)

Effective Portion:
Interest rate swaps	$	(0.1	)	Interest expense	$	(1.1	)	$	—
Foreign exchange forward contracts	(2.9		)	Cost of products sold	3.8			—
Foreign exchange forward contracts	—			SG&A expenses	0.1			—
Commodity contracts	(0.2		)	Cost of products sold	—			—

Ineffective Portion:
Foreign exchange forward contracts	—			Other expense (income), net	—			(0.5		)
Total in cash flow hedging	$	(3.2	)		$	2.8		$	(0.5	)



September 30, 2014
	Gain (Loss) in AOCI			Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)			Ineffective Portion Recognized in Income (Expense)

(in millions)

Effective Portion:
Interest rate swaps	$	0.3		Interest expense	$	(1.0	)	$	—
Foreign exchange forward contracts	7.5			Cost of products sold	(2.2		)	—
Foreign exchange forward contracts	0.3			SG&A expenses	—			—
Commodity contracts	(0.3		)	Cost of products sold	—			—

Ineffective Portion:
Foreign exchange forward contracts	—			Other expense (income), net	—			(1.0		)
Total for cash flow hedging	$	7.8			$	(3.2	)	$	(1.0	)

Net Investment Hedging

Derivative [Line Items]

Schedule of Derivative Instruments



September 30, 2015
	Gain (Loss) in AOCI		Consolidated Statements of Operations Location	Recognized in Income (Expense)

(in millions)

Effective Portion:
Foreign exchange forward contracts	$	9.5	Other expense (income), net	$	2.0
Total for net investment hedging	$	9.5		$	2.0



September 30, 2014
	Gain (Loss) in AOCI		Consolidated Statements of Operations Location	Recognized in Income (Expense)

(in millions)

Effective Portion:
Cross currency basis swaps	$	22.4	Interest income	$	0.5
			Interest expense	(1.7		)
Foreign exchange forward contracts	21.2		Other expense (income), net	0.5
Total for net investment hedging	$	43.6		$	(0.7	)

Fair Value Hedging

Derivative [Line Items]

Schedule of Derivative Instruments

The following table summarizes the notional amounts of fair value hedges by derivative instrument type at September 30, 2015 and the notional amounts expected to mature during the next 12 months:



	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

(in millions)

Interest rate swaps	$	45.0	$	45.0

Derivative Instruments, Gain (Loss)



	Consolidated Statements of Operations Location
		Three Months Ended September 30,					Nine Months Ended September 30,
(in millions)		2015		2014			2015		2014

Interest rate swaps	Interest expense	$	0.1	$	(0.1	)	$	0.2	$	0.1

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41678-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

FAIR VALUE MEASUREMENT (Tables)

9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Financial Assets and Liabilities that are Recorded at Fair Value and Classified Based on the Lowest Level of Input



	September 30, 2015
(in millions)	Total		Level 1		Level 2		Level 3

Assets
Interest rate swaps	$	0.2	$	—	$	0.2	$	—
Foreign exchange forward contracts	35.2		—		35.2		—
Total assets	$	35.4	$	—	$	35.4	$	—

Liabilities
Interest rate swaps	$	1.6	$	—	$	1.6	$	—
Commodity contracts	0.2		—		0.2		—
Foreign exchange forward contracts	6.2		—		6.2		—
Long-term debt	45.2		—		45.2		—
Total liabilities	$	53.2	$	—	$	53.2	$	—



	December 31, 2014
(in millions)	Total		Level 1		Level 2		Level 3

Assets
Interest rate swaps	$	0.8	$	—	$	0.8	$	—
Cross currency basis swaps	2.7		—		2.7		—
Foreign exchange forward contracts	45.4		—		45.4		—
DIO Corporation convertible bonds	57.7		—		—		57.7
Total assets	$	106.6	$	—	$	48.9	$	57.7

Liabilities
Interest rate swaps	$	1.1	$	—	$	1.1	$	—
Commodity contracts	0.2		—		0.2		—
Foreign exchange forward contracts	9.2		—		9.2		—
Long-term debt	106.1		—		106.1		—
DIO equity option contracts	0.1		—		—		0.1
Total liabilities	$	116.7	$	—	$	116.6	$	0.1

Reconciliation of the Company's Assets Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3)

The following table presents a rollforward of the Company’s Level 3 holdings measured at fair value on a recurring basis using unobservable inputs:



(in millions)	DIO Corporation Convertible Bonds			DIO Equity Options Contracts

Balance at December 31, 2014	$	57.7		$	(0.1	)
Sales, gross	(47.7		)
Unrealized loss:
Reported in AOCI, pretax	(10.0		)	—
Realized gain:
Reported in other expense (income), net	—			0.1
Balance at September 30, 2015	$	—		$	—

GOODWILL AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Changes In Goodwill Table Text Block

A reconciliation of changes in the Company’s goodwill is as follows:



(in millions)	Dental Consumables, Endodontic and Dental Laboratory Businesses			Healthcare, Orthodontic and Implant Businesses			Select Developed and Emerging Markets Businesses			Total

Balance at December 31, 2014	$	565.7		$	1,394.4		$	129.2		$	2,089.3
Effects of exchange rate changes	(6.5		)	(86.4		)	(12.1		)	(105.0		)
Balance at September 30, 2015	$	559.2		$	1,308.0		$	117.1		$	1,984.3

Reconciliation of Changes in the Company's Goodwill

Identifiable definite-lived and indefinite-lived intangible assets consist of the following:



	September 30, 2015							December 31, 2014
(in millions)	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount

Patents	$	165.3	$	(93.2	)	$	72.1	$	175.2	$	(95.5	)	$	79.7
Trademarks	64.1		(35.1		)	29.0		75.6		(37.1		)	38.5
Licensing agreements	34.0		(24.4		)	9.6		34.6		(22.8		)	11.8
Customer relationships	429.7		(120.2		)	309.5		452.9		(104.7		)	348.2
Total definite-lived	$	693.1	$	(272.9	)	$	420.2	$	738.3	$	(260.1	)	$	478.2

Indefinite-lived Trademarks and In-process R&D	$	180.2	$	—		$	180.2	$	192.6	$	—		$	192.6

Total identifiable intangible assets	$	873.3	$	(272.9	)	$	600.4	$	930.9	$	(260.1	)	$	670.8

SIGNIFICANT ACCOUNTING POLICIES Additional Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Mar. 31, 2015	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	$ 4.8		$ 8.5
Other noncurrent assets, net	54.2		90.5
Notes payable and current portion of long-term debt	453.2		111.8
Long-term debt	701.9		1,150.1
Corporate Bond Securities
Significant Accounting Policies [Line Items]
Sales, gross	47.7
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value	0.0		57.7
Trade Accounts Receivable
Significant Accounting Policies [Line Items]
Allowance for Doubtful Accounts Receivable, Current	$ 10.0		8.8
Adjustments for New Accounting Principle, Early Adoption [Member]
Significant Accounting Policies [Line Items]
Other noncurrent assets, net		$ 57.7	90.5
Notes payable and current portion of long-term debt		246.7	111.8
Long-term debt		1,076.2	1,150.1
Scenario, Previously Reported \| Adjustments for New Accounting Principle, Early Adoption [Member]
Significant Accounting Policies [Line Items]
Other noncurrent assets, net		61.3	94.3
Notes payable and current portion of long-term debt		247.6	112.8
Long-term debt		1,078.8	1,152.9
Restatement Adjustment \| Adjustments for New Accounting Principle, Early Adoption [Member]
Significant Accounting Policies [Line Items]
Other noncurrent assets, net		(3.6)	(3.8)
Notes payable and current portion of long-term debt		(0.9)	(1.0)
Long-term debt		$ (2.6)	$ (2.8)

STOCK COMPENSATION Stock Compensation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 7.4	$ 6.2	$ 18.5	$ 18.7
Nonqualified Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized compensation cost	11.5		$ 11.5
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term			1 year 6 months
Performance Based Restricted Stock and Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized compensation cost	24.8		$ 24.8
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	5.1	4.0	$ 12.5	12.1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term			1 year 4 months
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	7.1	6.0	$ 18.0	18.2
Cost of Sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 0.3	$ 0.2	$ 0.5	$ 0.5

STOCK COMPENSATION Total Stock Based Compensation Expense and the Tax Related Benefit (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 7.4	$ 6.2	$ 18.5	$ 18.7
Total related tax benefit	2.1	1.6	5.5	5.1
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	2.3	2.2	6.0	6.6
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 5.1	$ 4.0	$ 12.5	$ 12.1

COMPREHENSIVE INCOME Comprehensive Income - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation adjustments	$ 37.7	$ 198.6	$ 150.6	$ 227.3
Accumulated Other Comprehensive Income Loss Foreign Currency Translation Gains Net Of Tax	(267.5)		(267.5)		$ (117.1)
Accumulated Other Comprehensive Income Loss Foreign Currency Translation Losses Net Of Tax	(96.2)		(96.2)		(95.4)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation adjustments	(2.3)	(201.8)	(150.4)	(227.2)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax			185.5		$ 195.4
Net Investment Hedging \| Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	$ 0.5	$ 9.0	$ (0.8)	$ 5.9

COMPREHENSIVE INCOME Balances included in AOCI, Net of Tax, in the Consolidated Balance Sheets (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			$ (441.1)
Net (decrease) increase in other comprehensive income	$ (28.1)	$ (79.7)	46.2	$ 54.2
Ending balance	(587.5)		(587.5)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			(212.5)	141.0
Other comprehensive income (loss) before reclassifications			(151.2)	(221.3)
Amounts reclassified from accumulated other comprehensive income (loss)			0.0	0.0
Net (decrease) increase in other comprehensive income			(151.2)	(221.3)
Foreign currency translation related to acquisition of noncontrolling interests				(5.5)
Ending balance	(363.7)	(85.8)	(363.7)	(85.8)
Gain and (Loss) on Derivative Financial Instruments Designated as Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			(10.8)	(21.8)
Other comprehensive income (loss) before reclassifications			15.4	4.5
Amounts reclassified from accumulated other comprehensive income (loss)			(10.8)	6.0
Net (decrease) increase in other comprehensive income			4.6	10.5
Foreign currency translation related to acquisition of noncontrolling interests				0.0
Ending balance	(6.2)	(11.3)	(6.2)	(11.3)
Gain and (Loss) on Derivative Financial Instruments Designated as Net Investment Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			(112.7)	(151.1)
Other comprehensive income (loss) before reclassifications			4.4	27.5
Amounts reclassified from accumulated other comprehensive income (loss)			0.0	0.0
Net (decrease) increase in other comprehensive income			4.4	27.5
Foreign currency translation related to acquisition of noncontrolling interests				0.0
Ending balance	(108.3)	(123.6)	(108.3)	(123.6)
Net Unrealized Holding Gain (Loss) on Available-for-Sale Securities
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			8.5	12.7
Other comprehensive income (loss) before reclassifications			(4.8)	(0.2)
Amounts reclassified from accumulated other comprehensive income (loss)			(3.7)	0.0
Net (decrease) increase in other comprehensive income			(8.5)	(0.2)
Foreign currency translation related to acquisition of noncontrolling interests				0.0
Ending balance	0.0	12.5	0.0	12.5
Pension Liability Adjustments
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			(113.6)	(49.9)
Other comprehensive income (loss) before reclassifications			0.0	3.6
Amounts reclassified from accumulated other comprehensive income (loss)			4.3	1.4
Net (decrease) increase in other comprehensive income			4.3	5.0
Foreign currency translation related to acquisition of noncontrolling interests				0.0
Ending balance	(109.3)	(44.9)	(109.3)	(44.9)
Total DENTSPLY International Equity
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			(441.1)	(69.1)
Other comprehensive income (loss) before reclassifications			(136.2)	(185.9)
Amounts reclassified from accumulated other comprehensive income (loss)			(10.2)	7.4
Net (decrease) increase in other comprehensive income			(146.4)	(178.5)
Foreign currency translation related to acquisition of noncontrolling interests				(5.5)
Ending balance	$ (587.5)	$ (253.1)	$ (587.5)	$ (253.1)

COMPREHENSIVE INCOME Reclassification out of Accumulated Other Comprehensive Income (Expense) (Details) - USD ($)
$ in Millions

3 Months Ended

9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Reclassification of Acuumulated Other Comprehensive Income [Line Items]

Provision for income taxes

$ (19.6)

$ (21.2)

$ (63.2)

$ (69.9)

Net Income (Loss) Available to Common Stockholders, Basic

1.2

(2.4)

6.5

(7.4)

Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, before Tax

(5.1)

0.0

(5.1)

0.0

Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax

1.4

0.0

1.4

0.0

Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax

(3.7)

0.0

(3.7)

0.0

Gain and (Loss) on Derivative Financial Instruments Designated as Cash Flow Hedges

Reclassification of Acuumulated Other Comprehensive Income [Line Items]

Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest

2.8

(3.2)

11.6

(9.0)

Provision for income taxes

(0.2)

1.3

0.8

(3.0)

Net Income (Loss) Available to Common Stockholders, Basic

2.6

(1.9)

10.8

(6.0)

Pension Liability Adjustments

Reclassification of Acuumulated Other Comprehensive Income [Line Items]

Other Comprehensive Income (Loss), Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax

0.0

^[1]

0.0

^[1]

0.1

^[1]

Other Comprehensive Income (Loss) adjustment from AOCI,Pension and Other Postretirement Benefit Plans, for Net Gain (Loss), before Tax

(2.0)

^[1]

(0.7)

^[1]

(6.1)

(2.1)

Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest

(2.0)

(0.7)

(6.0)

(2.0)

Provision for income taxes

0.6

0.2

1.7

0.6

Net Income (Loss) Available to Common Stockholders, Basic

(1.4)

(0.5)

(4.3)

(1.4)

Cash Flow Hedging | Designated as Hedging Instrument

Reclassification of Acuumulated Other Comprehensive Income [Line Items]

Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net

2.8

(3.2)

11.6

(9.0)

Interest Expense | Cash Flow Hedging | Designated as Hedging Instrument | Interest Rate Swap

Reclassification of Acuumulated Other Comprehensive Income [Line Items]

Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net

(1.1)

(1.0)

(3.1)

(2.8)

Cost of Sales | Cash Flow Hedging | Designated as Hedging Instrument | Foreign Exchange Contract

Reclassification of Acuumulated Other Comprehensive Income [Line Items]

Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net

3.8

(2.2)

14.5

(5.5)

Cost of Sales | Cash Flow Hedging | Designated as Hedging Instrument | Commodity Contract

Reclassification of Acuumulated Other Comprehensive Income [Line Items]

Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net

0.0

(0.3)

(0.5)

Selling, General and Administrative Expenses | Cash Flow Hedging | Designated as Hedging Instrument | Foreign Exchange Contract

Reclassification of Acuumulated Other Comprehensive Income [Line Items]

Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net

$ 0.1

$ 0.0

$ 0.5

$ (0.2)

[1]	These accumulated other comprehensive income components are included in the computation of net periodic benefit cost for the three months ended September 30, 2015 and 2014 (see Note 8, Benefit Plans, for additional details).

EARNINGS PER COMMON SHARE Additional Information (Detail) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Antidilutive common stock options not included in the computation of diluted earnings per common share (in shares)	0.8	0.9	1.0	1.2

EARNINGS PER COMMON SHARE Computation of Basic and Diluted Earnings Per Common Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Net income attributable to DENTSPLY International	$ 84.5	$ 75.3	$ 192.6	$ 238.1
Shares
Basic (in shares)	139.8	141.8	140.0	141.9
Incremental shares from assumed exercise of dilutive options from stock-based compensation awards (in shares)	2.6	2.5	2.5	2.4
Diluted (in shares)	142.4	144.3	142.5	144.3
Earnings per common share
Basic (in dollars per share)	$ 0.60	$ 0.53	$ 1.38	$ 1.68
Diluted (in dollars per share)	$ 0.59	$ 0.52	$ 1.35	$ 1.65

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

BUSINESS COMBINATIONS - Other Disclosures (Details) $ in Millions	Sep. 15, 2015	Jan. 01, 2014 Entity	Mar. 15, 2016 USD ($)
Business Acquisition [Line Items]
Number of entities \| Entity		1
Termination Fees \| Scenario, Forecast \| Sirona Dental Systems Inc
Business Acquisition [Line Items]
Contingent fee			$ 205.0
Acquisition-related Costs \| Scenario, Forecast \| Sirona Dental Systems Inc
Business Acquisition [Line Items]
Contingent fee			15.0
Sirona Dental Systems Inc \| Common Stock
Business Acquisition [Line Items]
Sirona common stock conversion ratio	1.8142
Sirona Dental Systems Inc \| Termination Fees \| Scenario, Forecast
Business Acquisition [Line Items]
Contingent fee			280.0
Sirona Dental Systems Inc \| Acquisition-related Costs \| Scenario, Forecast
Business Acquisition [Line Items]
Contingent fee			$ 15.0

SEGMENT INFORMATION Additional Information (Detail)	9 Months Ended
SEGMENT INFORMATION Additional Information (Detail)	Sep. 30, 2015	Sep. 30, 2014
Dental Products
Segment Reporting Information [Line Items]
Percentage of sales, professional dental products	88.00%	88.00%

SEGMENT INFORMATION Net Sales (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Net sales	$ 648.9	$ 708.2	$ 2,003.2	$ 2,203.6
Operating Segments \| Dental Consumables, Endodontic and Dental Laboratory Businesses
Net sales	306.4	323.7	934.0	1,009.2
Operating Segments \| Healthcare, Orthodontic and Implant Businesses
Net sales	226.2	246.7	715.1	790.9
Operating Segments \| Select Developed and Emerging Markets Businesses
Net sales	$ 116.3	$ 137.8	$ 354.1	$ 403.5

SEGMENT INFORMATION Net Sales, Excluding Precious Metal Content (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue, Major Customer [Line Items]
Net Sales, excluding precious metal content	$ 629.3	$ 681.6	$ 1,935.6	$ 2,101.7
Precious metal content of sales	19.6	26.6	67.6	101.9
Net Sales, including precious metal content	648.9	708.2	2,003.2	2,203.6
Operating Segments \| Dental Consumables, Endodontic and Dental Laboratory Businesses
Revenue, Major Customer [Line Items]
Net Sales, excluding precious metal content	292.7	304.3	886.1	929.4
Net Sales, including precious metal content	306.4	323.7	934.0	1,009.2
Operating Segments \| Healthcare, Orthodontic and Implant Businesses
Revenue, Major Customer [Line Items]
Net Sales, excluding precious metal content	226.1	246.6	714.6	790.3
Net Sales, including precious metal content	226.2	246.7	715.1	790.9
Operating Segments \| Select Developed and Emerging Markets Businesses
Revenue, Major Customer [Line Items]
Net Sales, excluding precious metal content	110.5	130.7	334.9	382.0
Net Sales, including precious metal content	$ 116.3	$ 137.8	$ 354.1	$ 403.5

SEGMENT INFORMATION Intersegment Net Sales (Details) - USD ($)
$ in Millions

3 Months Ended

9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Segment Reporting, Revenue Reconciling Item [Line Items]

Total

$ 0.0

Intersegment Eliminations

Segment Reporting, Revenue Reconciling Item [Line Items]

Intersegment Eliminations

(140.0)

(147.0)

(432.5)

(464.1)

Intersegment Eliminations | Dental Consumables, Endodontic and Dental Laboratory Businesses

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenues

82.8

83.6

256.0

266.7

Intersegment Eliminations | Healthcare, Orthodontic and Implant Businesses

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenues

2.0

1.2

5.3

5.7

Intersegment Eliminations | Select Developed and Emerging Markets Businesses

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenues

3.4

9.7

Intersegment Eliminations | All Other

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenues

^[1]

$ 51.8

$ 58.8

$ 161.5

$ 182.0

[1]	Includes amounts recorded at one distribution warehouse not managed by named segments.

SEGMENT INFORMATION Segment Operating Income (Details) - USD ($)
$ in Millions

3 Months Ended

9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]

Segment operating income

$ 98.6

$ 109.6

$ 282.1

$ 342.3

Restructuring and other costs

6.6

2.5

50.9

4.5

Interest expense

9.6

12.7

30.1

35.4

Interest income

(0.4)

(1.4)

(1.8)

(4.6)

Other expense (income), net

(3.8)

0.8

(3.6)

1.8

Income before income taxes

93.2

97.5

257.4

309.7

Operating Segments

Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]

Segment operating income

132.6

126.0

393.9

404.9

Operating Segments | Dental Consumables, Endodontic and Dental Laboratory Businesses

Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]

Segment operating income

107.9

100.8

322.1

325.6

Operating Segments | Healthcare, Orthodontic and Implant Businesses

Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]

Segment operating income

28.0

26.9

82.5

83.5

Operating Segments | Select Developed and Emerging Markets Businesses

Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]

Segment operating income

(3.3)

(1.7)

(10.7)

(4.2)

Operating Segments | All Other

Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]

Segment operating income

^[1]

$ 27.4

$ 13.9

$ 60.9

$ 58.1

[1]	Includes the results of unassigned Corporate headquarter costs, inter-segment eliminations and one distribution warehouse not managed by named segments.

SEGMENT INFORMATION Assets (Details) - USD ($)
$ in Millions

Sep. 30, 2015

Dec. 31, 2014

Segment Reporting, Asset Reconciling Item [Line Items]

Assets

$ 4,402.2

$ 4,646.5

Operating Segments | Dental Consumables, Endodontic and Dental Laboratory Businesses

Segment Reporting, Asset Reconciling Item [Line Items]

Assets

1,333.9

1,358.0

Operating Segments | Healthcare, Orthodontic and Implant Businesses

Segment Reporting, Asset Reconciling Item [Line Items]

Assets

2,457.2

2,655.6

Operating Segments | Select Developed and Emerging Markets Businesses

Segment Reporting, Asset Reconciling Item [Line Items]

Assets

348.0

369.8

Operating Segments | All Other

Segment Reporting, Asset Reconciling Item [Line Items]

Assets

^[1]

$ 263.1

[1]	Includes the assets of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.

INVENTORIES Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
LIFO inventory amount	$ 8.7	$ 6.3
Inventory, LIFO reserve	6.4	6.1
Inventory valuation reserve	$ 37.6	$ 34.1

INVENTORIES Inventories (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Finished goods	$ 236.9	$ 253.3
Work-in-process	52.9	58.4
Raw materials and supplies	71.5	75.4
Inventory, net	$ 361.3	$ 387.1

BENEFIT PLANS Components of Net Periodic Benefit Cost (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Pension Plans, Defined Benefit
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	$ 4.3	$ 3.4	$ 13.0	$ 10.5
Interest cost	1.8	2.7	5.5	8.5
Expected return on plan assets	(1.3)	(1.3)	(4.1)	(4.1)
Amortization of prior service cost	0.0	0.0	(0.1)	(0.1)
Amortization of net loss	1.9	0.6	5.9	2.0
Defined Benefit Plan, Net Periodic Benefit Cost	6.7	5.4	20.2	16.8
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	0.1	0.1	0.3	0.2
Interest cost	0.1	0.1	0.5	0.4
Amortization of net loss	0.1	0.0	0.1	0.0
Defined Benefit Plan, Net Periodic Benefit Cost	$ 0.3	$ 0.2	$ 0.9	$ 0.6

BENEFIT PLANS Information Related to the Contributions to the Company's Benefit Plans (Details) $ in Millions	9 Months Ended
	Sep. 30, 2015 USD ($)
Pension Plans, Defined Benefit
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Actual contributions through September 30, 2015	$ 8.0
Projected for the remainder of the year	3.5
Defined Benefit Plan, Expected Contributions in Current Fiscal Year	11.5
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Actual contributions through September 30, 2015	0.3
Projected for the remainder of the year	0.3
Defined Benefit Plan, Expected Contributions in Current Fiscal Year	$ 0.6

RESTRUCTURING AND OTHER COSTS Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Incurred Cost	$ 6.6	$ 2.5	$ 50.9	$ 4.5
Dental Consumables, Endodontic and Dental Laboratory Businesses
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Incurred Cost	$ 34.0
Healthcare, Orthodontic and Implant Businesses
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Incurred Cost			$ 10.2

RESTRUCTURING AND OTHER COSTS Restructuring Accruals (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Mar. 31, 2015	Sep. 30, 2015
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 9.3	$ 9.3
Restructuring Charges		49.3
Amounts applied		(19.1)
Change in estimates		(1.7)
Ending Balance		37.8
Employee Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	6.0	6.0
Restructuring Charges		45.4
Amounts applied		(15.3)
Change in estimates		(1.6)
Ending Balance		34.5
Employee Severance \| Restructuring Fiscal 2013 And Prior Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	0.9	0.9
Restructuring Charges		0.1
Amounts applied		(0.6)
Change in estimates		(0.1)
Ending Balance		0.3
Employee Severance \| Restructuring Fiscal 2014 Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	5.1	5.1
Restructuring Charges		0.5
Amounts applied		(3.4)
Change in estimates		(0.2)
Ending Balance		2.0
Employee Severance \| Restructuring Fiscal 2015 Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	0.0	0.0
Restructuring Charges		44.8
Amounts applied		(11.3)
Change in estimates		(1.3)
Ending Balance		32.2
Contract Termination
Restructuring Reserve [Roll Forward]
Beginning Balance	2.2	2.2
Restructuring Charges		1.1
Amounts applied		(1.1)
Change in estimates		0.0
Ending Balance		2.2
Contract Termination \| Restructuring Fiscal 2013 And Prior Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	0.5	0.5
Restructuring Charges		0.0
Amounts applied		(0.2)
Change in estimates		0.0
Ending Balance		0.3
Contract Termination \| Restructuring Fiscal 2014 Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	1.7	1.7
Restructuring Charges		0.0
Amounts applied		(0.5)
Change in estimates		0.0
Ending Balance		1.2
Contract Termination \| Restructuring Fiscal 2015 Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	0.0	0.0
Restructuring Charges		1.1
Amounts applied		(0.4)
Change in estimates		0.0
Ending Balance		0.7
Other Restructuring
Restructuring Reserve [Roll Forward]
Beginning Balance	1.1	1.1
Restructuring Charges		2.8
Amounts applied		(2.7)
Change in estimates		0.1
Ending Balance		1.1
Other Restructuring \| Restructuring Fiscal 2013 And Prior Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	0.0	0.0
Restructuring Charges		0.0
Amounts applied		0.0
Change in estimates		0.0
Ending Balance		0.0
Other Restructuring \| Restructuring Fiscal 2014 Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	1.1	1.1
Restructuring Charges		0.2
Amounts applied		(0.8)
Change in estimates	0.1
Ending Balance		0.4
Other Restructuring \| Restructuring Fiscal 2015 Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 0.0	0.0
Restructuring Charges		2.6
Amounts applied		(1.9)
Change in estimates		0.0
Ending Balance		$ 0.7

RESTRUCTURING AND OTHER COSTS Provisions and Adjustments and Amounts Applied for All Plans by Segment (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2015 USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 9.3
Restructuring Charges	49.3
Amounts applied	(19.1)
Change in estimates	(1.7)
Ending Balance	37.8
Dental Consumables, Endodontic and Dental Laboratory Businesses
Restructuring Reserve [Roll Forward]
Beginning Balance	5.3
Restructuring Charges	34.7
Amounts applied	(10.2)
Change in estimates	(1.0)
Ending Balance	28.8
Healthcare, Orthodontic and Implant Businesses
Restructuring Reserve [Roll Forward]
Beginning Balance	3.8
Restructuring Charges	11.7
Amounts applied	(8.1)
Change in estimates	(0.7)
Ending Balance	6.7
Select Developed and Emerging Markets Businesses
Restructuring Reserve [Roll Forward]
Beginning Balance	0.1
Restructuring Charges	1.1
Amounts applied	(0.4)
Change in estimates	0.0
Ending Balance	0.8
All Other
Restructuring Reserve [Roll Forward]
Beginning Balance	0.1
Restructuring Charges	1.8
Amounts applied	(0.4)
Change in estimates	0.0
Ending Balance	$ 1.5

FINANCIAL INSTRUMENTS AND DERIVATIVES Cash Flow Hedges (Details) - Sep. 30, 2015 - Cash Flow Hedging - Designated as Hedging Instrument SFr in Millions, $ in Millions	USD ($)	CHF (SFr)
Derivative [Line Items]
Derivative, Notional Amount	$ 502.6
Derivative, Notional amount maturing within 12 months	314.3
Foreign Exchange Contract
Derivative [Line Items]
Derivative, Notional Amount	330.1
Derivative, Notional amount maturing within 12 months	246.6
Interest Rate Swap
Derivative [Line Items]
Derivative, Notional Amount	171.3	SFr 65.0
Derivative, Notional amount maturing within 12 months	66.7
Commodity Contract
Derivative [Line Items]
Derivative, Notional Amount	1.2
Derivative, Notional amount maturing within 12 months	$ 1.0

FINANCIAL INSTRUMENTS AND DERIVATIVES Gain (Loss) on AOCI - Cash Flow Hedges (Details) - Cash Flow Hedging - Designated as Hedging Instrument - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	$ (3.2)	$ 7.8	$ 17.8	$ 3.9
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	2.8	(3.2)	11.6	(9.0)
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	(0.5)	(1.0)	(0.3)	0.0
Interest Expense \| Interest Rate Swap
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	(0.1)	0.3	(1.4)	(0.2)
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	(1.1)	(1.0)	(3.1)	(2.8)
Cost of Sales \| Foreign Exchange Contract
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	(2.9)	7.5	19.1	3.9
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	3.8	(2.2)	14.5	(5.5)
Cost of Sales \| Commodity Contract
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	(0.2)	(0.3)	(0.2)	(0.1)
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0.0	0.0	(0.3)	(0.5)
Selling, General and Administrative Expenses \| Foreign Exchange Contract
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	0.0	0.3	0.3	0.3
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0.1	0.0	0.5	$ (0.2)
Other Expense \| Foreign Exchange Contract
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	$ (0.5)	$ (1.0)	$ (0.3)

FINANCIAL INSTRUMENTS AND DERIVATIVES Net Investment Hedges (Details) - Net Investment Hedging - Designated as Hedging Instrument - Foreign Exchange Contract $ in Millions	Sep. 30, 2015 USD ($)
Derivative [Line Items]
Derivative, Notional Amount	$ 409.9
Derivative, Notional amount maturing within 12 months	$ 226.2

FINANCIAL INSTRUMENTS AND DERIVATIVES Gain (Loss) on AOCI - Net Investment Hedges (Details) - Designated as Hedging Instrument - Net Investment Hedging - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	$ 9.5	$ 43.6	$ 6.1	$ 44.8
Derivative, Gain (Loss) on Derivative, Net	2.0	(0.7)	2.8	1.0
Cross Currency Basis Swaps Member
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net		22.4		19.3
Cross Currency Basis Swaps Member \| Interest Income
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net		0.5		1.9
Cross Currency Basis Swaps Member \| Interest Expense
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net		(1.7)		(1.6)
Cross Currency Basis Swaps Member \| Other Expense
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net	2.0	0.5	2.8	0.7
Foreign Exchange Contract
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	$ 9.5	$ 21.2	$ 6.1	$ 25.5

FINANCIAL INSTRUMENTS AND DERIVATIVES Fair Value Hedges (Details) - Interest Rate Swap - Designated as Hedging Instrument - Fair Value Hedging - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Derivative [Line Items]
Derivative, Notional Amount	$ 45.0		$ 45.0
Derivative, Notional amount maturing within 12 months	45.0		45.0
Interest Expense
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net	$ 0.1	$ (0.1)	$ 0.2	$ 0.1

FINANCIAL INSTRUMENTS AND DERIVATIVES Hedges not Designated (Details) - Not Designated as Hedging Instrument - USD ($)
$ in Millions

3 Months Ended

9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Derivative [Line Items]

Derivative, Notional Amount

$ 430.5

Derivative, Notional amount maturing within 12 months

424.1

Derivative, Gain (Loss) on Derivative, Net

(4.1)

$ (3.8)

2.0

$ (12.4)

Foreign Exchange Forward

Derivative [Line Items]

Derivative, Notional Amount

428.5

Derivative, Notional amount maturing within 12 months

423.3

Interest Rate Swap

Derivative [Line Items]

Derivative, Notional Amount

2.0

Derivative, Notional amount maturing within 12 months

0.8

Other Expense | Foreign Exchange Contract

Derivative [Line Items]

Derivative, Gain (Loss) on Derivative, Net

^[1]

(4.1)

36.8

3.7

31.6

Other Expense | Equity Option

Derivative [Line Items]

Derivative, Gain (Loss) on Derivative, Net

0.1

(0.2)

Other Expense | Cross Currency Basis Swaps Member

Derivative [Line Items]

Derivative, Gain (Loss) on Derivative, Net

^[1]

$ 0.0

$ (40.6)

$ (1.8)

$ (43.8)

[1]	The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances which are recorded in “Other expense (income), net” in the Consolidated Statements of Operations.

FINANCIAL INSTRUMENTS AND DERIVATIVES Balance Sheet Location (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	$ 25.6	$ 28.7
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value	5.1	7.5
Other Noncurrent Assets
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	4.7	12.6
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value	0.0	0.0
Accrued Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	2.7	3.5
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value	4.1	4.8
Other Noncurrent Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	1.2	2.1
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value	0.0	0.2
Foreign Exchange Forward \| Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	25.4	28.1
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value	5.1	4.8
Foreign Exchange Forward \| Other Noncurrent Assets
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	4.7	12.5
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value	0.0	0.0
Foreign Exchange Forward \| Accrued Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	1.1	2.7
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value	4.1	4.8
Foreign Exchange Forward \| Other Noncurrent Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	1.1	1.7
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value	0.0	0.0
Commodity Contract \| Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	0.0	0.0
Commodity Contract \| Other Noncurrent Assets
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	0.0	0.0
Commodity Contract \| Accrued Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	0.2	0.2
Commodity Contract \| Other Noncurrent Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	0.0	0.0
Interest Rate Swap \| Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	0.2	0.6
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value		0.0
Interest Rate Swap \| Other Noncurrent Assets
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	0.0	0.1
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value		0.0
Interest Rate Swap \| Accrued Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	1.4	0.6
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value		0.0
Interest Rate Swap \| Other Noncurrent Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	$ 0.1	0.4
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value		0.1
Dio Equity Option Contracts \| Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value		0.0
Dio Equity Option Contracts \| Other Noncurrent Assets
Derivative [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value		0.0
Dio Equity Option Contracts \| Accrued Liabilities
Derivative [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value		0.0
Dio Equity Option Contracts \| Other Noncurrent Liabilities
Derivative [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value		0.1
Cross Currency Basis Swaps Member \| Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value		2.7
Cross Currency Basis Swaps Member \| Other Noncurrent Assets
Derivative [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value		0.0
Cross Currency Basis Swaps Member \| Accrued Liabilities
Derivative [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value		0.0
Cross Currency Basis Swaps Member \| Other Noncurrent Liabilities
Derivative [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value		$ 0.0

FINANCIAL INSTRUMENTS AND DERIVATIVES Balance Sheet Offsetting (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Derivative Asset [Abstract]
Derivative Asset, Not Subject to Master Netting Arrangement	$ 35.4	$ 48.8
Derivative Asset	35.4	48.8
Derivative Asset, Securities Purchased under Agreements to Resell, Securities Borrowed, Collateral, Obligation to Return Securities	7.6	9.1
Derivative, Collateral, Obligation to Return Cash	0.0	0.0
Derivative Asset, Fair Value, Amount Offset Against Collateral	27.8	39.7
Derivative Liability [Abstract]
Derivative Liability, Not Subject to Master Netting Arrangement	8.0	10.7
Derivative Liability	8.0	10.7
Derivative Liability, Securities Sold under Agreements to Resell, Securities Loaned, Collateral, Right to Reclaim Securities	(7.6)	(9.2)
Derivative, Collateral, Obligation to Return Cash	0.0	0.0
Derivative Liability, Fair Value, Amount Offset Against Collateral	0.4	1.5
Foreign Exchange Contract
Derivative Asset [Abstract]
Derivative Asset, Not Subject to Master Netting Arrangement	35.2	45.4
Derivative Asset	35.2	45.4
Derivative Asset, Securities Purchased under Agreements to Resell, Securities Borrowed, Collateral, Obligation to Return Securities	7.6	7.8
Derivative, Collateral, Obligation to Return Cash	0.0	0.0
Derivative Asset, Fair Value, Amount Offset Against Collateral	27.6	37.6
Derivative Liability [Abstract]
Derivative Liability, Not Subject to Master Netting Arrangement	6.2	9.2
Derivative Liability	6.2	9.2
Derivative Liability, Securities Sold under Agreements to Resell, Securities Loaned, Collateral, Right to Reclaim Securities	(6.2)	(8.2)
Derivative, Collateral, Obligation to Return Cash	0.0	0.0
Derivative Liability, Fair Value, Amount Offset Against Collateral	0.0	1.0
Commodity Contract
Derivative Asset [Abstract]
Derivative, Collateral, Obligation to Return Cash	0.0	0.0
Derivative Liability [Abstract]
Derivative Liability, Not Subject to Master Netting Arrangement	0.2	0.2
Derivative Liability	0.2	0.2
Derivative Liability, Securities Sold under Agreements to Resell, Securities Loaned, Collateral, Right to Reclaim Securities	0.0	0.0
Derivative, Collateral, Obligation to Return Cash	0.0	0.0
Derivative Liability, Fair Value, Amount Offset Against Collateral	0.2	0.2
Interest Rate Swap
Derivative Asset [Abstract]
Derivative Asset, Not Subject to Master Netting Arrangement	0.2	0.7
Derivative Asset	0.2	0.7
Derivative Asset, Securities Purchased under Agreements to Resell, Securities Borrowed, Collateral, Obligation to Return Securities	0.0	0.2
Derivative, Collateral, Obligation to Return Cash	0.0	0.0
Derivative Asset, Fair Value, Amount Offset Against Collateral	0.2	0.5
Derivative Liability [Abstract]
Derivative Liability, Not Subject to Master Netting Arrangement	1.6	1.2
Derivative Liability	1.6	1.2
Derivative Liability, Securities Sold under Agreements to Resell, Securities Loaned, Collateral, Right to Reclaim Securities	(1.4)	(1.0)
Derivative, Collateral, Obligation to Return Cash	0.0	0.0
Derivative Liability, Fair Value, Amount Offset Against Collateral	$ 0.2	0.2
Cross Currency Basis Swaps Member
Derivative Asset [Abstract]
Derivative Asset, Not Subject to Master Netting Arrangement		2.7
Derivative Asset		2.7
Derivative Asset, Securities Purchased under Agreements to Resell, Securities Borrowed, Collateral, Obligation to Return Securities		1.1
Derivative, Collateral, Obligation to Return Cash		0.0
Derivative Asset, Fair Value, Amount Offset Against Collateral		1.6
Derivative Liability [Abstract]
Derivative, Collateral, Obligation to Return Cash		$ 0.0

FINANCIAL INSTRUMENTS AND DERIVATIVES Additional Information (Details) - group	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Sep. 30, 2015
Derivative [Line Items]
Maximum Length of Time Hedged in Interest Rate Cash Flow Hedge		18 months
Number of groups of significant interest rate swaps		2
Fair Value Hedging \| Private Placement Notes Member
Derivative [Line Items]
Debt Instrument Maturity Period		5 years
Interest Rate Swap \| Fair Value Hedging \| Private Placement Notes Member
Derivative [Line Items]
Derivative, Term of Contract	5 years
Currency Japanese Yen Member \| Interest Rate Swap
Derivative [Line Items]
Derivative, Term of Contract		5 years
Currency Swiss Franc Member \| Interest Rate Swap
Derivative [Line Items]
Derivative, Term of Contract		5 years

FINANCIAL INSTRUMENTS AND DERIVATIVES - Narrative (Details) SFr in Millions, ¥ in Billions	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Sep. 30, 2015 USD ($)	Sep. 30, 2015 CHF (SFr)	Sep. 30, 2015 JPY (¥)	Apr. 04, 2011 USD ($)	Feb. 28, 2010 USD ($)
Term Loan Agreement
Derivative [Line Items]
Derivative, Notional Amount \| ¥				¥ 12.6
Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative, Notional Amount		$ 430,500,000
Interest Rate Swap \| Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative, Notional Amount		2,000,000
Cross Currency Basis Swaps Member \| Designated as Hedging Instrument
Derivative [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax		3,300,000
Cash Flow Hedging \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative, Notional Amount		$ 502,600,000
Cash Flow Hedging \| Interest Rate Swap \| Term Loan Agreement
Derivative [Line Items]
Derivative, Fixed Interest Rate		0.20%	0.20%	0.20%
Cash Flow Hedging \| Interest Rate Swap \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative, Fixed Interest Rate		0.70%	0.70%	0.70%
Derivative, Notional Amount		$ 171,300,000	SFr 65.0
Fair Value Hedging \| Interest Rate Swap \| Private Placement Notes Member
Derivative [Line Items]
Derivative, Fixed Interest Rate					4.10%
Derivative, Notional Amount					$ 150,000,000.0
Debt Instrument, Face Amount						$ 250,000,000.0
Derivative, Term of Contract	5 years
Fair Value Hedging \| Interest Rate Swap \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative, Notional Amount		$ 45,000,000

FAIR VALUE MEASUREMENT Financial Assets and Liabilities that are Recorded at Fair Value and Classified Based on the Lowest Level of Input (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	$ 35.4	$ 106.6
Liabilities	53.2	116.7
Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0.2	0.8
Liabilities	1.6	1.1
Commodity Contract
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	0.2	0.2
Cross Currency Interest Rate Swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets		2.7
Foreign Exchange Forward
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	35.2	45.4
Liabilities	6.2	9.2
Corporate Bond Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets		57.7
Long-term Debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	45.2	106.1
Dio Equity Option Contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities		0.1
Fair Value, Inputs, Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0.0	0.0
Liabilities	0.0	0.0
Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	35.4	48.9
Liabilities	53.2	116.6
Fair Value, Inputs, Level 2 \| Interest Rate Swap
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0.2	0.8
Liabilities	1.6	1.1
Fair Value, Inputs, Level 2 \| Commodity Contract
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	0.2	0.2
Fair Value, Inputs, Level 2 \| Cross Currency Interest Rate Swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets		2.7
Fair Value, Inputs, Level 2 \| Foreign Exchange Forward
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	35.2	45.4
Liabilities	6.2	9.2
Fair Value, Inputs, Level 2 \| Long-term Debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	45.2	106.1
Fair Value, Inputs, Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0.0	57.7
Liabilities	$ 0.0	0.1
Fair Value, Inputs, Level 3 \| Corporate Bond Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets		57.7
Fair Value, Inputs, Level 3 \| Dio Equity Option Contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities		$ 0.1

FAIR VALUE MEASUREMENT Reconciliation Assets Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2015 USD ($)
Corporate Bond Securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 57.7
Sales, gross	(47.7)
Unrealized Loss Reported in AOCI	(10.0)
Reported in other expense (income), net	0.0
Ending Balance	0.0
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation
Unrealized Loss Reported in AOCI	(10.0)
Reported in other expense (income), net	0.0
Dio Equity Option Contracts
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Unrealized Loss Reported in AOCI	0.0
Reported in other expense (income), net	0.1
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation
Beginning Balance	0.1
Unrealized Loss Reported in AOCI	0.0
Reported in other expense (income), net	0.1
Ending Balance	$ 0.0

FAIR VALUE MEASUREMENT Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Corporate Bond Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Approximate stock volatility	40.00%
Discount rate	8.73%
Fixed rate senior notes $450 million due August 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, fixed rate	4.10%
Tranche C \| Unsecured Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	$ 450,000,000
Tranche B \| Unsecured Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	300,000,000
Tranche A \| Unsecured Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	$ 250,000,000
Private Placement Notes Member \| U.S. Dollar Denominated Expiring March 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, fixed rate	4.10%
Fixed Rate Senior Notes \| U.S. Dollar Denominated Due August 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, fixed rate	2.80%
Estimate of Fair Value, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt, Fair Value	$ 1,178,100,000	$ 1,286,200,000
Carrying (Reported) Amount, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt, Fair Value	$ 1,152,000,000	$ 1,258,900,000

INCOME TAXES Additional Information (Detail) - Future Period Member $ in Millions	9 Months Ended
	Sep. 30, 2015 USD ($)
Income Taxes [Line Items]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	$ 2.1
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	0.7
Unrecognized tax benefits, expiration of statues of limitation	$ 0.4

FINANCING ARRANGEMENTS Long-Term Borrowings (Detail) - USD ($)		3 Months Ended	9 Months Ended
	Oct. 29, 2015	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Jul. 01, 2015	Jul. 24, 2014
Debt Instrument [Line Items]
Long-term Debt			$ 109,100,000	$ 199,000,000
Line of Credit Facility, Remaining Borrowing Capacity			553,400,000
Commercial Paper
Debt Instrument [Line Items]
Long-term Debt		$ 100,000,000
Private Placement
Debt Instrument [Line Items]
Short-term Debt			75,000,000
Revolving Credit Agreement
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity						$ 500,000,000
Revolving Credit Agreement \| Credit Facility Agreement Through 2019
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					$ 500,000,000
Revolving Credit Agreement \| Credit Facility Agreement Through 2020
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					$ 452,000,000
Term Loan Agreement
Debt Instrument [Line Items]
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months			$ 8,800,000
Unsecured Debt \| Senior Notes 4.125%
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			4.125%
Unsecured Debt \| Senior Notes 4.125% \| Subsequent Event
Debt Instrument [Line Items]
Debt Instrument, Cash Tender Offer, Maximum Principal Authorized	$ 150,000,000.0
Debt Instrument, Cash Tender Offer, Consideration Payable	$ 160,300,000

GOODWILL AND INTANGIBLE ASSETS Reconciliation of Changes in Goodwill (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2015 USD ($)
Goodwill [Roll Forward]
Balance, beginning of the year	$ 2,089.3
Goodwill, Translation Adjustments	(105.0)
Balance, end of the year	1,984.3
Dental Consumables, Endodontic and Dental Laboratory Businesses
Goodwill [Roll Forward]
Balance, beginning of the year	565.7
Goodwill, Translation Adjustments	(6.5)
Balance, end of the year	559.2
Healthcare, Orthodontic and Implant Businesses
Goodwill [Roll Forward]
Balance, beginning of the year	1,394.4
Goodwill, Translation Adjustments	(86.4)
Balance, end of the year	1,308.0
Select Developed and Emerging Markets Businesses
Goodwill [Roll Forward]
Balance, beginning of the year	129.2
Goodwill, Translation Adjustments	(12.1)
Balance, end of the year	$ 117.1

GOODWILL AND INTANGIBLE ASSETS Identifiable Definite-Lived Intangible Assets (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 693.1	$ 738.3
Accumulated Amortization	(272.9)	(260.1)
Net Carrying Amount	420.2	478.2
Identifiable Intangible Assets Gross	873.3	930.9
Intangible Assets, Net (Excluding Goodwill)	600.4	670.8
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	180.2	192.6
Patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	165.3	175.2
Accumulated Amortization	(93.2)	(95.5)
Net Carrying Amount	72.1	79.7
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	64.1	75.6
Accumulated Amortization	(35.1)	(37.1)
Net Carrying Amount	29.0	38.5
Licensing Agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	34.0	34.6
Accumulated Amortization	(24.4)	(22.8)
Net Carrying Amount	9.6	11.8
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	429.7	452.9
Accumulated Amortization	(120.2)	(104.7)
Net Carrying Amount	$ 309.5	$ 348.2

GOODWILL AND INTANGIBLE ASSETS Intangible Assets Impairment (Details) $ in Millions	9 Months Ended
	Sep. 30, 2015 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment of Intangible Assets (Excluding Goodwill)	$ 3.7

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended			3 Months Ended
	Jan. 31, 2014	Dec. 31, 2006	Jun. 30, 2004	Sep. 30, 2015
San Francisco County California
Commitments and Contingencies Disclosure [Line Items]
Loss Contingency, Trial or Alternative Dispute Resolution			On June 18, 2004, Marvin Weinstat, DDS and Richard Nathan, DDS filed a class action suit in San Francisco County, California alleging that the Company misrepresented that its Cavitron® ultrasonic scalers are suitable for use in oral surgical procedures.
Loss Contingency, Lawsuit Filing Date			June 18, 2004
Loss Contingency, Name of Plaintiff			Marvin Weinstat, DDS and Richard Nathan, DDS
Eastern District Of Pennsylvania
Commitments and Contingencies Disclosure [Line Items]
Loss Contingency, Trial or Alternative Dispute Resolution	On January 20, 2014, the Company was served with a qui tam complaint filed by two former and one current employee of the Company under the Federal False Claims Act and equivalent state and city laws. The lawsuit was previously under seal in the U.S. District Court for the Eastern District of Pennsylvania	On December 12, 2006, a Complaint was filed by Carole Hildebrand, DDS and Robert Jaffin, DDS in the Eastern District of Pennsylvania (the Plaintiffs subsequently added Dr. Mitchell Goldman as a named class representative). The case was filed by the same law firm that filed the Weinstat case in California. The Complaint asserts putative class action claims on behalf of dentists located in New Jersey and Pennsylvania.
Loss Contingency, Lawsuit Filing Date	Jan. 20, 2014	December 12, 2006
Loss Contingency, Name of Plaintiff	Former and Current Employees	Carole Hildebrand, DDS and Robert Jaffin, DDS and Dr. Mitchell Goldman
Sirona Dental Shareholders Case
Commitments and Contingencies Disclosure [Line Items]
Loss Contingency, Trial or Alternative Dispute Resolution				On October 2, 2015 and October 5, 2015, the Company and its wholly-owned subsidiary Dawkins Merger Sub Inc. (“Merger Sub”) were served with two separate putative class action complaints filed in the Court of Chancery of the State of Delaware by purported stockholders of Sirona Dental Systems, Inc. (“Sirona”) against the members of Sirona’s Board of Directors, the Company, and Merger Sub.

Label	Element	Value
Treasury Stock [Member]
Stock Issued During Period, Value, Stock Options Exercised	us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised	$ 33,200,000
Additional Paid-in Capital [Member]
Dividends, Share-based Compensation, Cash	us-gaap_DividendsShareBasedCompensationCash	(200,000)
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	(11,200,000)
Parent [Member]
Dividends, Cash	us-gaap_DividendsCash	$ 30,300,000